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ABSTRACT OF THE DISSERTATION 
 
APTAMER SENSORS FOR DRUGS OF ABUSE AND MEDICAL BIOMARKERS: 
DESIGN, ENGINEERING, AND APPLICATION IN COMPLEX SAMPLES 
by 
 
Daniel Roncancio 
 
Florida International University, 2018 
Miami, Florida 
Professor Yi Xiao, Major Professor 
 
Aptamers are short oligonucleotide sequences (DNA or RNA) capable of high 
affinity and specific binding to a molecule or a family of molecules. Aptamers are 
lower in cost and exhibit higher reproducibility when compared to antibodies and 
thus are well-suited for recognition and detection of small molecular targets such 
as drugs of abuse and small medical biomarkers. While aptamers have been 
extensively utilized for development of small molecule sensors, several limitations 
prevent measurements of complex or real-world samples. This dissertation 
describes methods, technologies, and assays that were developed with the goal 
of producing and/or improving aptamer-based sensors for target detection in 
complex samples. Aptamer engineering is detailed as an important facet of 
maximizing aptamer-sensor sensitivity and specificity, along with adaptation to 
various read-out mechanisms for improved selectivity. In chapter 3, an aptamer 
vii  
sensor for cocaine is developed based on binding between the fluorophore 
ATMND to the cocaine aptamer which results in quenching (i.e., ‘turn-off’) of the 
fluorescence of ATMND. Cocaine binding results in displacement of the ATMND 
and recovery of the fluorescence signal. Detection of cocaine is demonstrated with 
an engineered cocaine aptamer with higher affinity for cocaine, permitting over a 
50-fold increase in sensitivity over other aptamer-based sensors. The method can 
be used in dilute biological fluids (e.g., saliva) with a single step reaction (seconds) 
and robust signal output. In chapter 4, a new adenosine specific aptamer is 
identified through rational engineering of a previously reported ATP-binding 
aptamer. The new adenosine aptamer is utilized to develop an electrochemical 
sensor for detection of adenosine in undiluted serum. The method displays 40-fold 
higher sensitivity in undiluted serum measurements over previously reported 
aptamer-based sensors for adenosine but also demonstrates specificity for 
adenosine over ATP, ADP and AMP that has not been previously reported. In 
chapter 5, a nuclease-guided truncation method is developed to yield optimal 
structure-switching aptamer sequences for the emergent illicit drug 
methylenedioxypyrovalerone (MDPV) and medical biomarkers ATP and 
deoxycorticosterone 21-glucoside (DOG). The method intelligently removes 
unessential nucleotides, producing truncated aptamer sequences with structure- 
switching functionality. This technique will be immediately useful for simple and 
low-cost development of aptamer-based electrochemical sensors. 
viii  
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CHAPTER 1 
 
Introduction 
 
1.1 Overview 
 
The detection of small molecules is integral to various aspects of modern living 
including medical diagnostics, environmental monitoring, and law enforcement. 
Accurate identification of a single molecule in a heterogeneous mixture requires 
high specificity to discriminate between competing molecules and high sensitivity 
to correctly measure the mean concentration of even trace analyte amounts. 
Instrumental analysis provides the highest discriminatory level (i.e., high 
specificity) and high sensitivity, thus it is generally accepted to be the gold standard 
of chemical analysis. However, these methods still require expensive and 
cumbersome machines, expert technicians, complex procedures, and long turn- 
around times for sample analysis. Biosensors are devices which combine highly 
specific and high-affinity molecular recognition of an analyte with simple and low- 
cost signal transduction. Biosensors have demonstrated similar analytical 
capabilities as expensive and complex analytical instruments but with exceptional 
convenience, instantaneous results, and lower cost. Today, a person can walk to 
a drugstore and purchase bio-sensing devices, aimed at detecting vastly different 
molecules including exogenous compounds such as drugs of abuse and 
endogenous compounds like medical biomarkers. Within minutes, an accurate 
representation of the analyte can be obtained in complex biological fluids without 
requiring any specialized training. The analyte concentration can be used to 
diagnose disease, monitor health status or drug use. 
2  
Biosensors are designed by combination of a recognition element and a 
transduction element. The recognition element provides specific binding and high- 
affinity interactions with the analyte against other molecules present in a sample. 
The transduction element converts the binding interaction between the recognition 
element and the analyte into a measurable signal that can be interpreted visually 
or instrumentally. Recognition elements include biological molecules such as 
antibodies, enzymes and more recently, aptamers (i.e., DNA/RNA 
oligonucleotides). Antibody-based biorecognition is still widespread because of the 
excellent analytical characteristics of antibodies (high specificity and sensitivity) 
and nearly sixty years of research and development.1 More than two million 
antibodies are commercially available from hundreds of companies.2 Several 
examples of antibody-based sensors are commonly known to the general 
population including: pregnancy tests, ovulation kits, and drug screening 
immunoassays. Unfortunately, the generation of antibodies requires animal 
immunization which is not universally applicable for every molecule, such as in the 
case of immunosuppressive molecules and toxins.3,4 Additionally, antibody 
reliability and specificity is highly source-dependent with susceptibility to batch-to- 
batch variation and non-specific binding to off-target molecules. Indeed, landmark 
publications have been retracted because of difficulty in reproducing scientific 
findings obtained with antibodies. Authors of such publications have advised 
caution and recommended careful validation of individual antibody assays.5,6 In 
the context of small molecule detection, antibody-based sensors require 
specialized molecular components to transduce the binding interaction with the 
3  
analyte into a measurable signal. For example, a chemically labeled target can be 
added to the sample as a signal marker by competing with the free target for the 
antibody binding site.7 Only the labeled-target can report interactions with the 
antibody and any disturbance of the interaction is a representative signal that free 
target is present. Similarly, an enzyme-labeled target can be utilized to compete 
with the free target. The enzyme-labeled target is inactivated when bound to the 
antibody but can regain its activity upon displacement from the antibody by free 
target in the sample. The active enzyme-labeled target can transform an 
exogenous substrate to generate a signal dependent on free target concentration. 
Thus, in the context of small molecule sensors, antibodies still do not offer direct 
transduction (i.e., signal generation) of analyte-antibody interactions. 
Aptamers are single-stranded oligonucleotide-based bio-affinity reagents which 
mimic the specific recognition ability of antibodies but are chemically generated 
and synthesized, overcoming the necessity for animal immunization while 
providing unmatched reproducibility.8 Aptamers have been continuously improved 
since the first generation back in 1990, with recent examples demonstrating 
analytical performance surpassing antibodies.9 Aptamers are generated through 
an artificial evolutionary process that screens >1013 unique sequences and only 
evolves sequences that provide high specificity and high affinity for the target of 
interest. The screening process can be customized to provide either exceptional 
specificity or cross-reactivity for a family of molecules. For example, counter- 
selection targets can be added to the process to remove sequences with affinity 
for molecules with unwanted binding. Evolved aptamers can be accurately 
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sequenced and chemically synthesized with incredible reproducibility and purity. 
Thus, aptamers always display the same inherent specificity and affinity regardless 
of the source unlike antibodies. However, it should be noted that aptamer-target 
interactions are dependent on experimental factors such as buffer conditions and 
temperature, thus reproducibility also depends on the experimenter. Aptamers are 
especially useful for detection of small molecule analytes with several 
methodologies not requiring addition of exogenous reagents or multiple assay 
steps. For example, Plaxco et al. described an aptamer-sensor that could be 
implanted in ambulant animals to monitor small molecule drugs in real time.10 
Aptamers can be engineered and chemically modified with functional groups for 
signal transduction of the aptamer-analyte interaction, including analytical signal 
via a change in color11,12, fluorescence13,14, or electrochemical current15,16. 
Accordingly, aptamers have been utilized to develop biosensors for small 
molecules including exogenous drugs of abuse, endogenous medical biomarkers, 
and environmental toxins and pollutants.17 
1.2 Motivation and goal 
 
While the advantages of aptamer technology are well established, aptamer-based 
sensors have not reached commercial availability because of issues including 
limited sensitivity, inconsistent specificity (i.e., cross-reactivity) and susceptibility 
to matrix interferents (i.e., selectivity).8 The goal of this dissertation is to understand 
the physical characteristics of aptamer-target interactions and apply aptamer 
engineering to increase aptamer-sensor sensitivity, specificity (i.e., cross- 
reactivity) and selectivity (i.e., specificity against matrix interferents), resulting in 
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small molecule sensors that are functional in complex matrices. I describe methods 
of aptamer engineering and innovations in signal transduction that display 
improved analytical characteristics with specific examples including a cocaine 
sensor that improved the detection limit of aptamer-based sensors by 50-fold, an 
adenosine sensor that improved specificity against ATP, ADP and AMP and 
simultaneously demonstrated a 40-fold improvement in sensitivity and a method 
to generalize the aptamer engineering process for small molecule detection in 
highly complex samples like serum. 
1.3 Scope of the dissertation 
 
To demonstrate the utility of aptamer-sensors for small molecule detection, I 
present three projects that focus on rational aptamer engineering to improve the 
sensitivity and specificity of current aptamers and outline a method to easily 
generate aptamer-based sensors that can be utilized in complex samples such as 
undiluted serum. Aptamer-based sensing of cocaine was previously limited 
because of insufficient sensitivity. In chapter 3, I describe a simple fluorescence 
aptamer-based sensor that I developed to detect cocaine in biological fluids and 
other complex samples such as alcoholic and soft drinks, exhibiting detection limits 
50-fold higher than other aptamer-based sensors, yet displaying near 
instantaneous results, utilizing low cost reagents and microliter volumes. In chapter 
4, I demonstrate the ability to engineer currently available aptamers to modulate 
their specificity. The previously reported adenosine aptamer is cross-reactive for 
multiple adenosine derivatives including adenosine, adenosine monophosphate, 
adenosine diphosphate and adenosine triphosphate, molecules which are all 
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simultaneously present in biological fluids. The inherent cross-reactivity prevents 
utilization of this aptamer for specific measurements of adenosine, a well-known 
disease biomarker. An adenosine sensor is demonstrated that can instantaneously 
detect adenosine in undiluted serum, providing a tool for disease diagnostics and 
pathophysiological research. The sensor exhibits 40-fold higher sensitivity 
compared to previously reported aptamer-based sensors with specificity against 
ATP, ADP and AMP that has not been demonstrated elsewhere. Conventional 
aptamer structures lack the structure-switching functionality required for 
development of sensors applicable in complex samples. In chapter 5, I develop a 
nuclease-guided system to intelligently truncate aptamer sequences yielding 
aptamers which demonstrate optimal structure-switching functionality. The 
produced aptamers can be easily incorporated to sensors functional in undiluted 
complex samples. Specific examples include truncation of an 
methylenedioxypyrovalerone (MDPV)-binding aptamer, multiple steroid-binding 
aptamers, and an adenosine triphosphate (ATP)-binding aptamer. In combination, 
the body of work demonstrates the utility of aptamers for small molecule sensing, 
the ability and tools to engineer aptamers to maximize sensitivity and specificity 
and the adaptability of aptamers to methodologies that can be readily employed in 
highly complex samples such as biological fluids. 
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CHAPTER 2 
 
Background and literature review 
 
2.1 Biosensors 
 
Biosensors are devices utilized to measure the presence or concentration of a 
specific molecule in a sample solution. Biosensors are characterized by two main 
components: the recognition and transducing elements.18–20 The recognition 
element is the biomolecule component that provides discriminatory power for a 
single molecule and a high affinity interaction that permits measurements of even 
trace amounts of analyte. Recognition elements include enzymes, antibodies and 
more recently, aptamers (i.e., DNA/RNA molecules). For example, pregnancy tests 
utilize antibodies specific for human chorionic gonadotropin (hCG) to diagnose 
pregnancy at home. Levels of hCG hormone rise rapidly and consistently after 
implantation with concentrations peaking at 10,000-fold above basal levels.21–23 
While recognition elements provide extensive discriminatory power and strong 
interactions with a given molecule, they seldom transduce such an interaction into 
a measurable signal. The transducing element can convert the interaction between 
the recognition element and the analyte into a measurable signal. In the context of 
the pregnancy test, multiple antibodies work in tandem to transduce binding of 
hCG. The first antibody is immobilized on a test line and the second antibody is 
labeled with gold nanoparticles which provide a color signal (fig. 1a). In the 
presence of hCG, the two antibodies meet at the test line to form a sandwich 
around the hCG molecule as they bind different epitopes of the molecule and a 
colored line is observed on the test line from the gold nanoparticle-labeled antibody 
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(fig. 1c and d, positive). In the absence of hCG, the line is not formed as the two 
antibodies do not bind each other (fig. 1d, negative).24,25 A control line is also 
included to signal the presence of the unbound antibody (fig. 1d). The recognition 
element and the transducer determine the analytical performance of a biosensor. 
The recognition element directly determines the specificity of the sensor while the 
sensitivity is a function of both the recognition element but is also strongly 
influenced by the transduction element. Biosensors are often characterized by the 
type of recognition element that is employed. 
 
 
Figure 1. Example of a biosensor for human chorionic gonadotropin (hCG) and its 
utility in pregnancy diagnosis. 
(a) Two antibodies specific for hCG are utilized. One antibody is immobilized on 
the test line and a second antibody is covalently labeled with gold nanoparticles 
for signal transduction. (b) Movement of the analyte and the labeled-antibody bring 
the analyte near the immobilized antibody. (c) If hCG is present in the sample, it 
will bind to the immobilized antibody and attract the secondary labeled antibody, 
forming a sandwich complex with a color line appearing on the test line. In the 
absence of hCG, the labeled antibody does not bind to the test line thus no color 
is observed. A control line is also utilized which binds the labeled antibodies. (d) 
Example results with a positive (two lines), negative (one line) and an intermediate 
sample that might be difficult to interpret. (Adapted from Koczula et al.).25 
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2.2 Antibody-based biosensors 
 
Antibodies dominate the biosensor field because of their analytical performance 
and wealth of methods available for detection of proteins and small molecules 
directly in complex samples. Generation of antibodies is achieved through 
repetitive immunization of an animal with a target of interest.2,26 Thus, production 
of antibodies often requires several months of development and there exist 
prevalent batch-to-batch variability and experimental reproducibility concerns that 
have been well-documented in several articles.5,27 Binding interactions are often 
described in terms of a dissociation constant –wherein the smaller the value, the 
stronger the interaction– with antibodies demonstrating dissociation constants of 1 
– 1,000 picomolar (10-12).27 Thus, antibody-based sensors are highly sensitive. 
Once isolated, antibodies can be used in a variety of methods to couple the binding 
interaction with an appropriate transduction mechanism. Small molecule detection 
requires exogenous labeled-targets that act as signal markers and compete with 
the free target for antibody binding sites.28 Thus, detection of a small molecule 
analyte requires multiple steps and relatively high-cost. Commercial assays are 
available for small molecules with assays including competitive enzyme-linked 
immunosorbent assay (ELISA), homogenous enzyme linked immunoassays, and 
kinetic interaction of microparticles in solution (KIMS). 
2.2.1 Competitive enzyme-linked immunosorbent assay (ELISA) 
 
All variations of ELISA assays require competition between a labeled-target or an 
immobilized target with free target in the test sample for a limited number of 
antibody binding sites.29 For example, the small molecule target can be passively 
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immobilized onto a plate surface. The unknown sample is mixed along with a 
limited amount of the appropriate antibody and incubated in the microplate well. 
Competition between the free target and the immobilized target will determine the 
amount of antibody that is specifically absorbed onto the plate wall by binding to 
the immobilized drug.30 If there is no drug present in the sample, most of the 
antibody will bind to the well of the plate. If drug is present, the antibody will be 
bound to the free drug and be discarded during the washing steps that remove 
nonspecifically bound molecules. To quantify the amount of antibody left on the 
plate wall, a secondary enzyme-labeled antibody is utilized with affinity for the first 
antibody and an enzyme label such as horseradish peroxidase (HRP), which can 
convert a substrate to give a signal.29,31 Several substrates are compatible with 
HRP, and the absorbance of the solution can be read with a plate reader to 
determine the drug concentration. The disadvantages of the assay are the long 
incubation times required and the necessity for multiple washing steps. 
2.2.2 Homogenous enzyme-linked immunoassays 
 
These immunoassays utilize an enzyme-linked target and the inhibition of the 
enzyme-linked target activity by antibody binding.32 A drug of interest is labeled 
with an enzyme such as glucose-6-phosphate dehydrogenase (G6PDH), and 
mixed with the sample of interest where the enzyme-labeled drug and the free drug 
compete for a limited number of antibody binding sites.33 The drug concentration 
is measured in terms of enzyme activity as it is modulated by binding to the 
antibody relative to the concentration of free drug in the sample. When displaced 
by free target binding to the antibody, the active enzyme converts nicotinamide 
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adenine dinucleotide (NAD) to NADH, resulting in a change in the absorbance of 
the solution that can be measured.33 The assay displays great sensitivity and 
relatively fast detection but might suffer from cross-reactivity with off-target 
molecules and high cost.33 
2.2.3 Kinetic interaction of microparticles in solution (KIMS) 
 
Microparticles are covalently modified with the drug of interest. In solution, these 
microparticles are dispersed and do not block transmission of light. However, if 
drug specific antibodies are added to the solution, it results in aggregation of the 
microparticles because of organized lattice formation by binding interactions 
between the antibodies and the drug-conjugated microparticles.7 The aggregated 
particles effectively block light transmission through the sample, resulting in 
increased absorbance.7 A sample that does not contain the drug of interest will not 
change the absorbance of the sample. Samples that are drug positive will inhibit 
the formation of the aggregated particles by competition for antibody binding sites 
producing changes in the absorbance.34 The absorbance difference before and 
after addition of sample can be utilized to calculate the drug content.34 
2.3 Aptamers 
 
Aptamers are chemically generated oligonucleotide-based recognition molecules 
which mimic the binding specificity of antibodies for specific targets with high- 
affinity interactions but offer low-cost production, high reproducibility and ease of 
chemical functionalization.39 Design of an aptamer-based biosensor from scratch 
requires generation of an appropriate aptamer and adaption to a signal 
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transduction mechanism. Aptamers have thus far been used to design biosensors 
for small molecules, proteins, cells and ions.8 An incredible number of analytical 
methodologies have been utilized in concert with aptamers to produce signaling 
including electrochemistry, fluorescence, color-change, and mass-change 
techniques.35–37 
2.3.1 Discovery of aptamers and SELEX 
 
The isolation of aptamers was first described by two independent research groups 
in 1990. Tuerk and Gold termed the process of isolating such molecules as SELEX 
(Systematic Evolution of Ligands by Exponential Enrichment) and Ellington and 
Szostak coined the term aptamer –the output of SELEX (derived from Greek word 
meaning to fit).38,39 The first SELEX experiment consisted of mutating part of a 
sequence with a random 8-nt loop (each nucleotide position has a distinct 
nucleotide A, T, C or G; thus 48 ~ 65,000 distinct sequences in the library). The 
library of sequences was utilized to perform multiple rounds of competitive binding 
and amplification of binding-competent sequences. The result was two sequences 
that could bind the target from the starting library of 65,000.39 While initially met 
with skepticism about the adaptability to other targets, SELEX has proven to be a 
reliable method to isolate DNA/RNA molecules that can recognize several types 
of targets including small molecules, proteins, and small ions.40,41 
2.3.2 Systematic evolution by exponential enrichment (SELEX)42–45 
 
The SELEX process consists of various steps to isolate a single binding sequence 
from a rich and extensive set of unique aptamer sequences (termed a library). The 
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library is made up of distinct oligonucleotide molecules (between 1013-15) with 
constant primer regions (for amplification) and a variable region of random 
nucleotides that vary in length to increase or fix molecular complexity (for binding 
interactions).8 The library is incubated with the target (i.e., molecule of interest), 
allowing for binding interactions between the aptamers and the target. The target 
will naturally have an affinity for certain sequences that exhibit the maximum 
interaction with the target based on the DNA fold or structure.26 The sequences 
which bind the target are then separated from sequences that do not bind. 
Separation can be accomplished by various mechanisms and is one of the main 
differential factors of SELEX technologies. Separation can be achieved by 
immobilization of the target onto a surface (see figure 2). The library is incubated 
through a target-immobilized column and the binding aptamers are retained on the 
column. Non-binding sequences are washed out and discarded while retained 
aptamers are specifically eluted by addition of high concentrations of free target. 
For small molecules, the immobilization utilizes an important functional group 
which might prevent display of all functional groups of the target to the aptamer 
library. To overcome the issue of immobilizing the target, the library can be 
immobilized instead by hybridization to a column-conjugated complementary 
strand.45 Addition of the target of interest results in displacement only of aptamers 
that can undergo target-induced structure-switching from the hybridized 
conjugated strand to a target-bound complex. The rest of non-binding and 
immobilized aptamers can be discarded. The separation step is crucial as any non- 
binding sequences must be discarded. Following separation, the remaining 
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binding sequences are amplified by polymerase chain reaction (PCR). The PCR 
reaction relies on enzymes to make copies of the remaining sequences in the 
library. The binding sequences are amplified so the new library can have multiple 
copies of a singular sequence, referred to as an enriched library. The PCR process 
produces ds-DNA that must be separated into ss-DNA before the second round of 
incubation with the target. Separation can be accomplished by primers that are 
specifically labeled with affinity reagents such as biotin or with phosphate end 
groups that are resistant to nuclease digestion. The enriched library of ss-DNA can 
once again be incubated with the target. The same steps are followed for various 
rounds of competitive binding until only the best binding sequences are present in 
the enriched library. After each round of SELEX, elution profiles can be utilized to 
determine whether the enriched library has increased in affinity to the target as 
compared to the starting library and the library in the previous round. Thus, SELEX 
has been regularly termed an artificial evolutionary process. Depending on the 
SELEX methodology and the separation efficiency between binders and non- 
binders, this can be from three to thirty rounds.8,17 Once the library has been 
enriched, the remaining winning sequences are cloned and sequenced to 
determine the exact nucleotide composition. The selection process can be done 
completely in vitro, without requirements for animal immunization.27 Additionally, 
the specificity of the aptamer can be carefully controlled by removal of sequences 
which bind to undesirable molecules. The process yields aptamers that have high 
specificity and sensitivity that can be applied for use in biosensors with unmatched 
reproducibility if purity and reaction conditions are accurately controlled. 
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Figure 2. Example schematic of target-immobilized SELEX. The target molecule 
is immobilized on a surface and incubated with the DNA library. Non-binders are 
washed out and the binders are eluted specifically and amplified via PCR. The 
enriched library is utilized for a second round of separation. The selection rounds 
are repeated until library enrichment is observed by affinity measurements after 
each round. Once satisfactory enrichment has been achieved, the remaining 
aptamer pool is cloned, sequence and characterized. (Adapted from Ruigrok et 
al.).26 
2.3.3 Aptamer-based sensors for small molecules 
 
Aptamers have been utilized to measure various types of small molecules 
including medical biomarkers, drugs of abuse, and therapeutic drug molecules.17 
Importantly, aptamers can be synthesized or modified with added chemical 
functionality which instills new properties apart from target recognition such as 
direct signal transduction upon target binding.8 While well established, aptamer 
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sensors for small molecules still suffer from insufficient sensitivity, inconsistent 
specificity and difficulty in detection of analytes in complex samples.46 Aptamers 
for small molecules generally exhibit equilibrium dissociation constants in the 
micromolar range, about 100-fold lower as compared to antibodies.8,27 Thus, the 
sensitivity of aptamer-based sensors is limited by the intrinsic aptamer affinity to 
the targets and lack of appropriate transduction mechanisms that can maximize 
the native affinity instead of reducing it. Additionally, several widely utilized small 
molecule aptamers, such as the ATP-binding aptamer, exhibit cross-reactivity with 
molecules that are simultaneously present in biological samples, preventing target 
quantitation in biological samples.47 Finally, new methods are needed for universal 
adaptation of currently reported aptamers to transduction mechanisms which can 
function in complex matrices. Current methods rely on difficult, laborious and 
expensive trial-and-error methodologies that are not convenient or universally 
applicable.17,48 
2.4 Cocaine 
 
Cocaine is an illicit drug under the Controlled Substances Act with a designation 
of schedule II; this designation is reserved for drugs that have little medical use 
and an extremely high potential for abuse.49,50 Cocaine is a small molecule (<300 
daltons) that still ranks as one the highest illegally consumed and trafficked drugs 
in the world, according to the United Nations Office of Drug and Crime.51 Cocaine 
affects individuals by inhibiting the reuptake of neurotransmitters in the reward 
pathway such as dopamine. Drug effects produce exhilaration, euphoria, 
increased heart rate, rage, and others.52,53 Apart from the wanted drug effects, 
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cocaine can cause severe health difficulties after prolonged and repeated 
consumption such as organ failure.54 Thus, cocaine remains one of the most tested 
drugs in law enforcement, criminal investigations and drug withdrawal programs. 
Cocaine is quickly metabolized upon consumption with the major metabolite in 
urine being benzoylecgonine.55,56 Benzoylecgonine is present in urine at 
concentrations >100 mg/L for up to 24 hours after consumption while cocaine is 
present at levels >65 mg/L in urine within 8 hours and at trace levels thereafter.56 
Cocaine can also be found in saliva and serum at concentrations <0.4 mg/L. Thus 
commercial immunoassays detect benzoylecgonine in urine rather than cocaine 
as a presumptive test of cocaine use.33,56 
2.4.1 Cocaine metabolite detection with antibodies 
 
Various antibody-based assays are commercially available and widely employed 
with a positive result cut-off level of 0.3 µg/L.33 The EMIT II assay employs a 
glucose-6-phosphate dehydrogenase (G6PDH) enzyme conjugated to 
benzoylecgonine and benzoylecgonine specific antibodies for detection.32 If the 
cocaine metabolite is present in a biological sample, the free benzoylecgonine will 
compete for binding with the G6PDH-linked benzoylecgonine. The displacement 
of G6PDH-linked benzoylecgonine leads to reactivation of enzymatic activity and 
transformation of nicotinamide adenine dinucleotide (NAD) to NADH, resulting in 
a change in the absorbance of the solution that can be measured via 
spectroscopy.33 Competitive ELISA can also be employed for cocaine metabolite 
detection. The method consists of immobilizing benzoylecgonine specific 
antibodies onto a microplate well. A mixture of enzyme-labeled benzoylecgonine 
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is then incubated on the microplate well with the tested sample. Competition for 
the immobilized antibody binding sites is utilized to calculate the percent of labeled 
drug that binds to the immobilized antibody. Other immunoassays for cocaine 
metabolite rely on similar competition mechanisms between labeled 
benzoylecgonine and free benzoylecgonine in the sample matrix. These 
immunoassay methods exhibit cross-reactivity that depends on the specificity of 
the antibody and are susceptible to batch-to-batch variation. Additionally, the 
antibodies must be carefully stored and transported and exhibit limited shelf life. 
2.4.2 Cocaine detection with aptamers 
 
The cocaine aptamer was isolated by Milan Stojanovic and co-workers in 2000.57 
The original aptamer was termed MNS-4.1 and had a three-way junction 
secondary structure. The three-way junction is a description of three distinct 
intramolecular helices present around a central target-binding pocket. It has been 
postulated that the binding pocket at the junction of the helices is a highly 
hydrophobic environment because of unstacked nucleotides at the terminal of 
each junction displaying hydrophobic surfaces to the internal pocket.58 The 
isolated cocaine-binding aptamer has been utilized in several major sensor 
categories: (1) as a fully stable and singular three-way junction aptamer in dye- 
displacement assays, (2) as a singular, flexible aptamer in structure-switching 
assays and (3) as a split structure wherein the aptamer is a composed of two 
separate strands that can hybridize in the presence of cocaine.57,59,60 The latter 
two categories suffer from limited sensitivity as it has been experimentally 
determined that destabilizing or splitting of the aptamer structure reduces the 
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binding affinity for cocaine.61,62 For example, Stojanovic et al. initially demonstrated 
a fluorescence sensor by splitting the aptamer to produce target-induced self- 
assembly of the complementary fragments. One fragment was labeled with a 
fluorescent molecule while the other fragment was labeled with a quencher 
molecule. When cocaine was not present, the two fragments existed separately 
and thus a high fluorescence signal could be measured. Cocaine would induce 
self-assembly of the two fragments and bring the quencher near the fluorescent 
molecule, turning off the fluorescent signal. In this way, cocaine could be detected 
and differentiated from highly similar molecules, including benzoylecgonine which 
varies at a single functional group. Unfortunately, splitting of the aptamer reduces 
binding affinity for cocaine, limiting the sensitivity of the sensor. Stojanovic and co- 
workers later developed a more sensitive cocaine assay by stabilizing the three- 
way junction structure for a high affinity interaction with cocaine. They discovered 
that the colorimetric dye Cy7 could bind to the binding pocket in the absence of 
cocaine but was quickly displaced upon cocaine-aptamer specific binding, 
resulting in change of the color of the solution.60 In this circumstance, the affinity 
of the aptamer was conserved, leading to higher sensitivity as compared to the 
split aptamer design. Thus, an important structural feature for cocaine sensing is 
conserving or improving the high affinity interaction and coupling it with a sensitive 
transduction mechanism. However, the strategy has not been regularly reported 
with most transduction systems using cocaine-induced structure-switching 
including electrochemistry, fluorescence, absorbance, and microcantilevers.60,63,64 
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2.4.3 (2)-amino-5,6,7-trimethyl-1,8-naphthyridine (ATMND) 
 
The small molecule ATMND is a fluorescent dye that was developed for DNA 
single nucleotide polymorphism (SNP) typing. The ATMND molecule was 
specifically designed to bind to nucleobases opposite an abasic site (a space 
where a nucleotide is missing) by pseudo-hydrogen bonding to the unpaired 
nucleobase opposite the abasic site and stacking interactions with the neighboring 
nucleotides.65 Formation of hydrogen bonds and stacking in the DNA helix affects 
the fluorescence of the molecule. Free in solution, ATMND is highly fluorescent 
when excited at 358 nm. However, when bound inside the DNA helix, ATMND is 
non-fluorescent.66 The base opposite the abasic site determines the binding affinity 
of ATMND, with strong binding with cytosine (C) and thymine (T) but not but 
Adenine or guanine (A and G).67 Abasic sites can be artificially incorporated onto 
synthesized DNA or be mimicked by hybridization of DNA that leaves an empty 
base site in the sequence, thus aptamers can be functionalized with a high-affinity 
binding site for ATMND.68–70 Accordingly, ATMND has been utilized in various 
aptamer-based assays as a fluorescence reporter.69–71 For example, Xiang et al. 
developed an aptamer-sensor where ATMND is initially bound to an artificial 
abasic site by hybridization of an aptamer sequence with a short-competing 
oligonucleotide molecule. Target binding results in displacement of the hybridized 
oligo, thus disrupting the binding site and displacing ATMND form the aptamer. 
The fluorescence of the displaced ATMND can be correlated to the target 
concentration.69,71 Additionally, ATMND was also found to bind to C-C mismatched 
nucleotides in DNA stems, a property that has been exploited for detection of 
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analytes via displacement of ATMND from the C-C binding site.72 These strategies 
require chemical modification of the aptamer or addition of an anti-sense strand. 
Modification of the aptamer reduces the inherent binding affinity of the aptamer 
and limits the sensitivity of the assay. 
2.5 Adenosine 
 
Adenosine is an endogenous molecule present throughout the body with extensive 
roles in extracellular signaling pathways.73 Adenosine is primarily but not 
exclusively produced by metabolism of adenosine triphosphate, adenosine 
diphosphate and adenosine monophosphate outside of the cell by transformation 
of ATP to AMP by the enzyme CD39 followed by transformation of AMP to Ade by 
CD73.74 Outside the cell, adenosine signaling functions by binding to four distinct 
adenosine specific receptors: A1, A2a, A3, and A2b.73 Adenosine is the main agonist 
of these receptors, initiating signaling pathways that affect immune response, 
inflammation, blood flow and neurotransmitter release. Adenosine has been found 
at physiological concentrations of 30 – 300 nM under physiological conditions but 
at concentrations above 10 µM under pathological conditions (i.e., disease states) 
such as cellular stress, cell damage, hypoxia and cancer.73,75–77 In cancer 
pathogenesis, adenosine can act as an immunosuppressive signaling molecule by 
binding to the A2a receptor.78 It has been shown experimentally that mice lacking 
this receptor can recuperate from tumors, indicating the role of adenosine in 
actively preventing activation of tumor preventing cells. As the role of adenosine in 
immune response and inflammation needs to be explicitly understood, improved 
tools to measure adenosine concentration are urgently needed. 
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2.5.1 Adenosine concentration measurements 
 
Current methods to measure adenosine concentration in biological samples 
include high performance liquid chromatography (HPLC), capillary electrophoresis 
(CE), micro-dialysis, and enzyme-based sensors.76,77,79 For example, HPLC can 
readily detect adenosine with a simple absorbance detector as adenosine has a 
distinct absorbance. More recently, HPLC has been coupled with mass 
spectrometry to produce lower limits of detection and ability to measure more 
complex samples.80 However, such methods cannot be used for real-time 
detection, and also require complex sample handling and instrumentation. 
Adenosine is quickly metabolized or transported inside of cells, thus real-time 
monitoring of adenosine concentration might be better suited for more accurate 
diagnostics.75 Additionally, adenosine concentration might vary close to the cell 
surface, where adenosine is commonly produced. Thus, cell anchored recognition 
elements might provide accurate concentration measurements of adenosine, 
however such methods do not currently exist. The closest direct sensor for 
adenosine is by use of enzymatic recognition. These sensors utilize enzymes that 
can catalyze the transformation of adenosine into inosine, xanthine and other by 
products eventually leading to the production of hydrogen peroxide, which can be 
readily detected using electrochemistry or spectroscopy.81 Immobilization of these 
enzymes inside a membrane bound to an electrode surface provides a sensor 
methodology that can readily measure adenosine with much higher temporal 
resolution and can be surgically implanted to measure adenosine in situ. 
Unfortunately, insertion of these sensors into tissue causes damage that results in 
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release of ATP and thus affects the actual physiological concentration of 
adenosine. These sensors are also prone to interference from endogenous 
molecules such as inosine and xanthine, which are commonly found in biological 
fluids.81,82 
2.5.2 Aptamer-based adenosine measurements 
 
Huizenga et al. isolated the ATP-binding aptamer in 1995.47 The aptamer can bind 
to multiple adenosine derivatives including adenosine, adenosine 
monophosphate, adenosine diphosphate, and adenosine triphosphate.47,83 
Unfortunately, these molecules are simultaneously present in biological fluids.84,85 
Therefore, the current ATP-binding aptamer cannot be utilized for specific 
determinations of adenosine concentration in complex samples or clinically 
relevant diagnostics. Most publications have utilized the ATP-binding aptamer as 
a test bed for a transduction method rather than attempting to address the issue 
of specificity. For example, Lu et al. developed a sensor that used time-resolved 
luminescence for detection of adenosine in undiluted serum samples.46 However, 
the method displayed cross-reactivity with adenosine phosphate derivatives and 
displayed limited sensitivity (60 µM). Only one reported aptamer structure is 
specific for adenosine against negatively charged phosphate derivate molecules. 
Stojanovic et al. isolated an adenosine binding aptamer that was engineered to 
provide significant binding affinity for adenosine and decrease affinity with linear 
phosphate derivatives because of steric repulsion as argued by the authors. 
However, the Stojanovic aptamer structure has not been studied in detail and its 
application for complex sample measurements has not been determined.86 
24  
2.5.3 Aptamer engineering 
 
An important aspect of aptamer-sensor development is the need to instill signal 
reporting functionalities to aptamers and to fine-tune the affinity and specificity of 
the aptamer. Aptamer engineering can include mutation of nucleotides in the 
sequence, addition of nucleotides or removal of non-essential nucleotides.47 
Several examples in the literature have demonstrated increased aptamer 
performance after aptamer engineering.48,86,87 
2.5.4 Electrochemical aptamer-based (E-AB) sensors 
 
Electrochemical detection of molecules by linking with aptamer recognition is an 
extremely powerful technology that can be utilized in complex samples such as 
whole blood.10,88 The technique was inspired by electrochemical detection of DNA 
via immobilized DNA probes mimicking molecular beacons that were covalently 
labeled with a ferrocene tag which is an electroactive molecule.89 In the absence 
of DNA target, the immobilized stem-loop probe keeps the ferrocene tag near the 
electrode surface, with large currents being measured. Binding of the immobilized 
probe to a target DNA resulted in formation of double-stranded DNA structures that 
separated the electroactive group from the electrode surface. The distance directly 
affected the rate of electron transfer between the electroactive molecule and the 
electrode surface, thus the change in current could be used to determine the 
amount of DNA bound to the immobilized probe.89 Soon thereafter, aptamers were 
immobilized onto electrode surfaces (via strong thiol-gold bonds) and covalently 
labeled with methylene blue, an electroactive molecule.90 Xiao et al. first developed 
a signal-off sensor where the immobilized aptamer was separated from the 
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electrode surface by binding to thrombin (a relatively large molecule), resulting in 
reduced mobility of the aptamer and a reduction in the measured current.91 The 
native aptamer structure can also be engineered to maintain a flexible and open 
conformation which places the electroactive molecule far from the electrode 
surface, inhibiting the transfer of electrons.92 Target-binding can induce aptamer 
folding around the target causing the electroactive molecule to approach the 
surface and increase the rate of electron transfer. Thus, the current measured 
increases as target is added to the solution.93 An important aspect of E-AB sensors 
is the preparation of the aptamer-immobilized electrode.94 The aptamer is 
immobilized by addition of a thiol chemical group to one end of the aptamer. Gold 
electrodes can then form strong bonds with the thiol group, causing immobilization 
of the aptamer to the gold surface.95 While the thiol-gold bond is very strong, the 
nitrogenous bases of the DNA sequence are known to weakly interact with the gold 
surface.96 Thus, short alkane-thiol molecules can be added to prevent adsorption 
of the nitrogenous bases to the electrode surface.95 These short molecules form 
strong interactions with the gold surface and organize in neat monolayers because 
of hydrophobic interactions between the alkane chains of the immobilized 
molecules. Their role is to keep the aptamers in a ‘standing’ direction by preventing 
absorption of the nitrogenous bases to the electrode surface and to carefully 
control the density of immobilized aptamers at the electrode surface.95,97,98 Once 
prepared, the aptamer-bound electrodes can be utilized repeatedly by directly 
submerging into a sample of interest. A voltage is applied to the electrode to 
interrogate the electroactive molecule and measure the resulting current. 
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2.6 Aptamer structure-switching 
 
Aptamer isolation techniques often utilize libraries that have highly stable 
secondary structures with static conformations, requiring substantial testing to 
affirm or instill structure-switching upon target binding.17,48,62,83 Lack of structural 
change prevents adaptation to signaling mechanisms, as most require significant 
differences between the target-free structure and target-bound structure. Aptamer 
truncation describes a general process of removing nucleotides in the aptamer 
sequence that are not essential for binding, destabilizing the structure and instilling 
structure-switching functionality to the truncated aptamer.48,62,99 Aptamer 
truncation can be attained by manually removing bases from various parts of the 
aptamer to deduce the primary binding site but it is laborious and expensive 
because it requires characterization of multiple aptamer derivatives. Generally, 
most techniques rely on similar trial-and-error mechanisms until a short aptamer 
sequence is identified.17,100,101 For example, the cocaine aptamer was previously 
engineered to destabilize the target-free structure, with aptamer folding only 
occurring when cocaine was bound to the aptamer.102 The signaling occurred 
through a fluorescent label that was attached to one end of the aptamer and a 
quenching molecule attached to the opposite end. In the absence of cocaine, the 
two molecules were spatially separated but upon target-binding the molecules 
were in proximity. Thus, cocaine could modulate the fluorescence signal although 
affinity was compromised because of destabilization of the aptamer binding site. 
While functional, this technique is not easily adapted to other aptamers, requiring 
extensive work to deduce the target binding site and the minimum number of 
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nucleotides to provide binding affinity to the target. Therefore, other ways have 
been developed to instill structure-switching functionality. For example, a short 
complementary DNA strand can be used to hybridize with part of the aptamer 
sequence and block the binding site of the analyte.83 The length of the competing 
sequence is carefully designed to allow target-induced displacement. If the length 
of the competitor sequence is too long, the target would not be able to displace the 
competitor. While this method is easier to use with various aptamers, there is 
severe reduction in the affinity of the aptamer to the target because of the inherent 
competition imposed by the competing DNA strand.46,83 
2.6.1 Nuclease-guided truncation of aptamers 
 
Several purified enzymes are commercially available for a wide range of 
applications in transformation of DNA molecules. These enzymes often display 
incredible specificity for a specific structure of DNA, such as double-stranded DNA 
or single-stranded DNA. Thus, these enzymes can be utilized to probe the changes 
in the DNA conformation upon target-binding. 
2.6.2 Exonuclease I (Exo I) 
 
Exonuclease I is an enzyme purified from E. coli with a high level of specificity for 
hydrolysis of single-stranded DNA but with little to effect on double-stranded 
DNA.103 The enzyme can hydrolyze ss-DNA from the 3’- end stepwise, releasing 
single mononucleotides. The enzyme requires a divalent cation for catalysis and 
optimally performs under basic conditions. The enzyme has been previously 
utilized to detect small molecules with aptamer recognition.104 In the absence of 
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target, the aptamers have a conformation that is hydrolyzed by Exo I however upon 
binding to the target, the aptamer-target complex is not susceptible to enzymatic 
digestion. Addition of SYBR gold DNA binding dye was utilized to measure the 
amount of aptamer product left and correlated with the concentration of target. 
2.6.3 Exonuclease III (Exo III) 
 
Exonuclease III is an enzyme purified from E. coli that can catalyze the hydrolysis 
of various types of DNA. Exonuclease III can perform activities such as digestion 
of double-stranded DNA from the 3’- end of DNA, at blunt ends or at recessed 3’- 
ends but is not able to digest 3’- extensions longer than 4 nucleotides.105,106 The 
digestion results in release of mononucleotides and formation of single stranded 
DNA. Exonuclease III also displays endonuclease activity at abasic sites, resulting 
in nicks of the DNA sequence and formation of separate DNA fragments, and 
phosphatase activity for cleaving phosphate 3’ ends to 3’-OH, as well as Rnase H 
activity for catalyzing the hydrolysis of RNA/DNA hybrids.107,108 
Exonuclease III has been employed to truncate aptamer sequences to yield 
structure-switching aptamers and also to determine the binding sites of proteins to 
DNA. Such footprinting studies were based on the inhibition of the enzyme as it 
approached the protein-DNA binding site, producing leftover DNA fragments that 
could be visualized via gel electrophoresis to approximate the binding site by 
comparison to a control sample.109 A similar inhibition effect was discovered by 
Wang et al. where formation of aptamer-target complexes can inhibit the hydrolysis 
of aptamers by exonuclease III 4-nt away from the presumed binding site. In the 
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absence of binding target, exo III can completely digest the aptamer molecule. 
Furthermore, the yielded truncated aptamer sequences were shown to undergo 
target-induced structure-switching. The method demonstrated a general and 
simple platform to truncate stable, folded aptamers to yield structure-switching 
capable aptamer sequences.110 
2.6.4 T5 exonuclease 
 
The enzyme T5-exonuclease can preferentially digest 5’ overhangs, flaps and 
linear single- and double-stranded DNA in the 5’ to 3’ direction.111 The enzyme 
structure has been previously elucidated, with a small opening that is big enough 
to allow the threading of single-stranded DNA but not double-stranded DNA.112 
The enzyme T5 can bind to a 5’ overhang and thread the single-stranded 
sequence through the active site arch until reaching a junction of double-stranded 
DNA. The enzyme then hydrolyzes the threaded DNA resulting in a blunted dsDNA 
and a single-stranded fragment. The active site of the enzyme is lined with 
hydrophobic residues that presumably stabilize the threading of single-stranded 
DNA, and binding of divalent ions at the active site that mediate the hydrolysis 
reaction.113 A variety of divalent metal ions can be used as cofactors of T5 
exonuclease, with different ions modulating the activity of the enzyme.114 T5 
exonuclease has been described as a complementary enzyme to exonuclease III, 
which has similar activity but in the 3’ to 5’ direction. Exonuclease III has been 
utilized for determination of the binding site of molecules to DNA, thus it is possible 
that T5 exonuclease could perform a similar function. 
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2.6.5 Methylenedioxypyrovalerone (MDPV) 
 
The drug MDPV is an illicit substance under the Controlled Substances Act. It is 
listed as a schedule I drug with a high potential for abuse and no known medical 
use. The drug was initially part of the ‘bath salt’ epidemic, commonly sold as a 
product not meant for human consumption at convenience stores or over the 
Internet.115 The effect of MDPV is mediated by inhibiting dopamine reuptake and 
thus creating exhilaration with similar effects as drugs like cocaine and 
amphetamine.116 The common dosage of MDPV is in the milligram range and can 
be consumed in various ways such as snorting or smoking. Long term effects apart 
from addiction are not widely known although like cocaine, inhibition of the reward 
uptake pathway can have damaging health consequences.117 Detection of MDPV 
is an increasing concern for law enforcement and health administration. Antibody- 
based tests are available for screening of MDPV, with common confirmatory 
methods including GC/MS and other chromatography-mass spectrometry 
methods.118,119 However, MDPV is part of a family of drugs that have been 
extensively modified to avoid detection. Unfortunately, current immunoassays only 
recognize few structures thus new assays are urgently needed to screen the drug 
family rather than a single molecule specifically.120 
2.6.6 Adenosine triphosphate (ATP) 
 
Adenosine triphosphate (ATP) has various roles in cell signaling such as 
inflammation and immune response .74 Adenosine triphosphate is present 
intracellularly (i.e., inside the cell) at relatively high concentrations, between 5-10 
mM.121 The ATP molecule is amphiphilic, with hydrophobic groups as a result of 
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the nitrogenous base and hydrophilic because of the highly charged phosphate 
groups. A recent report suggest that the high intracellular concentration of ATP is 
because of the role of ATP as a hydrotrope, a compound that can facilitate 
solubilization of hydrophobic compounds.121 Adenosine triphosphate is 
transported to the outside of the cell by specific channel transporters and 
exocytosis.122 Outside the cell, it effects its signaling function by binding to a wide 
range of ATP receptors (termed P2 receptors).123 Its cellular signaling affects 
mechanisms such as inflammation and immune response. ATP can be reliably 
measured by the luciferase reaction. Luciferase can utilize ATP to oxygenate 
luciferin, producing light as a result.84 ATP concentration can be measured by the 
amount of light that is produced. More recent reports have outlined a method to 
immobilize this enzyme to cell membranes, permitting in situ measurements of 
ATP concentration in real time.124 Aptamer-sensors have also been designed for 
specific detection of ATP albeit with high dissociation constants and cross- 
reactivity with ADP.125 
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CHAPTER 3 
 
A Label-Free Aptamer-Fluorophore Assembly for Rapid and Specific 
Detection of Cocaine in Biofluids 
We report a rapid and specific aptamer-based method for one-step cocaine 
detection with minimal reagent requirements. The feasibility of aptamer-based 
detection has been demonstrated with sensors that operate via target-induced 
conformational change mechanisms, but these have generally exhibited limited 
target sensitivity. We have discovered that the cocaine-binding aptamer MNS-4.1 
can also bind the fluorescent molecule 2-amino-5,6,7-trimethyl-1,8-naphthyridine 
(ATMND) and thereby quench its fluorescence. We subsequently introduced 
sequence changes into MNS-4.1 to engineer a new cocaine-binding aptamer (38- 
GC) that exhibits higher affinity to both ligands, with reduced background signal 
and increased signal gain. Using this aptamer, we have developed a new sensor 
platform that relies on the cocaine-mediated displacement of ATMND from 38-GC 
as a result of competitive binding. We demonstrate that our sensor can detect 
cocaine within seconds at concentrations as low as 200 nM, which is 50-fold lower 
than existing assays based on target-induced conformational change. More 
importantly, our assay achieves successful cocaine detection in body fluids, with 
a limit of detection of 10.4, 18.4, and 36 μM in undiluted saliva, urine, and serum 
samples, respectively. 
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3.1 Introduction 
 
Cocaine is a central nervous system stimulant that increases levels of 
dopamine126,127 and potently inhibits neurotransmitter reuptake at the synapse.128– 
132 Abuse of cocaine has been shown to cause anxiety, paranoia, mood 
disturbances, organ damage, and violent behavior.52,133,134 Therefore, rapid 
detection of cocaine is needed to confirm suspicion of recent use in impaired driver 
investigations or to assist in overdose treatment in medical emergency settings. 
Various immunoassays have been developed for the detection of cocaine and/or 
its major metabolite benzoylecgonine in biofluids, including the enzyme-linked 
immunosorbent assay (ELISA)135 and the EMIT II Plus Cocaine Metabolite 
Assay.136 Unfortunately, the use of these assays is often limited because of the 
high cost of generating antibodies and issues with poor specificity. These antibody- 
based tests often cannot distinguish between the targeted drug and structurally 
similar substances, resulting in cross-reactivity-related false positives.137,138 
Aptamers are single-stranded RNA or DNA molecules selected in vitro via 
Systematic Evolution of Ligands by Exponential Enrichment (SELEX)39 to 
specifically bind to targets with high affinity, and they offer a practical alternative to 
antibodies for the detection of nucleic acids, proteins, and small molecules. 
Compared to antibodies, aptamers are relatively fast and cheap to produce and 
can be chemically synthesized with extreme accuracy and reproducibility.26,139 
Aptamer-based sensors have been gaining popularity because of their simplicity 
and specificity. For example, derivatives of the MNS-4.1 cocaine-binding 
aptamer57 have been labeled with sensing elements such as fluorophore/quencher 
34  
pairs,59 magnetic or metallic nanoparticles,11,140,141 quantum dots,142,143 and 
methylene blue64,144 to achieve specific detection of cocaine. In the absence of 
cocaine, the aptamer population exists in an equilibrium state consisting of both 
folded and unfolded structures,62 where the folded structures generate a 
background signal. When challenged with cocaine, the unfolded aptamers 
undergo a target-induced conformational change and form a noncanonical three- 
way junction that binds cocaine,62 producing a signal change. This limited target- 
induced fluorescence change resulted in a high detection limit (10 μM) even under 
optimal conditions, and the reason may be due to inefficient proximity quenching, 
low aptamer-target binding affinity, or both.59 
Different strategies such as target displacement have been used to increase the 
sensitivity of aptamer-based detection. For example, Stojanovic’s group used 
unmodified MNS-4.1 (Figure 3, MNS-4.1) to construct a colorimetric cocaine 
sensor based on cocaine-mediated displacement of a cyanine dye 
(diethylthiotricarbocyanine iodide; Cy7) from the dye-aptamer complex.60 They 
observed that the absorbance of Cy7 at 760 nm decreased with increasing cocaine 
concentrations in the range of 2 to 600 μM. Compared to the corresponding 
fluorescence sensor that exhibited less sensitivity due to intrusive covalent 
modifications on the aptamer,59 the sensitivity of the Cy7-based displacement 
assay was improved due to the high binding affinity of the unmodified MNS-4.1 
aptamer for cocaine.59,60,145 However, the limit of detection of this sensor was still 
limited to 2 μM as a result of high background signal from the weak interaction 
between Cy7 and MNS-4.1.60 
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Figure 3. (Top) Structures of the MNS-4.1, 38-GT, and 38-GC aptamers. 
These aptamers are predicted to fold into three helical stems built around a three- 
way junction. Stem 1 of MNS-4.1 contains three putative noncanonical base pairs, 
which have been substituted for Watson–Crick base pairs in 38-GT. 38-GC was 
further stabilized by converting the G–T wobble pair in stem 3 to a matched G–C 
base pair. (Bottom) Scheme of cocaine detection with the 38-GC aptamer sensor. 
38-GC stably folds in the absence of ligand at room temperature. ATMND binding 
to the aptamer quenches the molecule’s fluorescence, but after challenging this 
complex with cocaine, the competitive binding displaces ATMND from the binding 
site. The released ATMND generates a readily detectable fluorescent signal, 
indicating the presence of the cocaine target. 
 
In this work, we found that the MNS-4.1 cocaine binding aptamer can also bind the 
fluorescent dye 2-amino-5,6,7-trimethyl-1,8-naphthyridine (ATMND), quenching 
its fluorescence. In the presence of cocaine, however, the bound ATMND is 
competitively displaced, generating a rapid fluorescent readout as the released 
molecule is highly fluorescent in solution. Based on our characterization of this 
competitive binding of the cocaine target and ATMND signal reporter to the same 
aptamer, we further improved the performance of our aptamer sensor by deriving 
a new variant (Figure 3, 38-GC) of MNS-4.1 that stably assumes a predominantly 
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folded conformation at equilibrium. Using this optimized aptamer, we developed a 
rapid and selective assay for the detection of cocaine at concentrations as low as 
200 nM within 20 seconds, ∼50-fold lower than assays based on target-induced 
conformational change,140 but in less time and with fewer reagent 
requirements.146–148 Importantly, our sensor can also rapidly achieve cocaine 
detection at micromolar concentrations in body fluids such as urine, saliva, and 
serum. 
3.2 Materials 
 
ATMND was purchased from Ryan Scientific, and 3,3′-diethylthiatricarbocyanine 
iodide (Cy7) was purchased from Sigma-Aldrich; any dilution or stock solution was 
prepared with dimethyl sulfoxide (DMSO). Cocaine hydrochloride was purchased 
from Sigma-Aldrich, and benzoylecgonine tetrahydrate was purchased from 
Cerilliant Corporation. Both 50 mM stock solutions were prepared in acidic 
deionized water solution (pH 4.5) and stored at 4 °C. All DNA aptamers were 
ordered from Integrated DNA Technologies with high performance liquid 
chromatography (HPLC) purification and dissolved to a concentration of 500 μM in 
1 × filtered Tris-EDTA buffer (10 mM Tris, 1 mM EDTA, pH 8.0). DNA 
concentrations were measured on a NanoDrop 2000 (Thermo Scientific). DNA 
sequences are listed below: 
• 38-GT: 5′ GGG AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CTC CC 
3′; 
• 36-GT: 5’ GG AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CTC C 3’; 
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• 34-GT: 5’ G AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CTC 3’; 
 
• 32-GT: 5’ AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CT 3’; 
 
• 30-GT: 5’ GA CAA GGA AAA TCC TTC AAT GAA GTG GGT C 3’; 
 
• 38-GC: 5′ GGG AGA CAA GGA AAA TCC TTC AAC GAA GTG GGT CTC CC 
3′; 
• 38-GC M1: 5′ GGG AGA CAA GGA AAA TCC TCT AAC GAA GTG GGT CTC 
CC 3′; 
• 38-GC M2: 5′ GGG AGA CAA GGA AAA TCC TAC AAC GAA GTG GGT CTC 
CC 3′; 
• MNS-4.1: 5′ GGG AGA CAA GGA TAA ATC CTT CAA TGA AGT GGG TCG 
ATA 3′ 
3.3 Methods 
 
ATMND Binding and Cocaine Displacement Experiments 
 
For cocaine detection, we prepared 96 μL of reaction buffer (10 mM Tris, 0.01 mM 
MgCl2, pH 7.4), 1 μL of aptamer (final concentration 2 μM), and 1 μL of ATMND 
(final concentration 0.25 μM) solution. Each 98 μL reaction was loaded into one 
well of a 96-well plate. Fluorescence readings were taken 3 min apart to determine 
the stability of the signal, with excitation at 358 nm and emission at 405 nm. After 
the signal stabilized for 15 min, a 2 μL cocaine solution (0–2.5 mM) was added to 
each well using a multichannel pipet while monitoring the fluorescence signal. 
Samples were prepared in triplicate with average values used to plot the figures. 
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3.3.1 Detection with Cy7 
 
We performed the same set of experiments with the same solutions as described 
above for ATMND, but with 1 μL (final concentration 7 μM) of Cy7 instead of 
ATMND. The absorbance was recorded at 760 nm. 
3.3.2 ITC Experiments 
 
ITC experiments were performed with a MicroCal iTC200 instrument (GE 
Healthcare). All measurements were performed in 10 mM Tris buffer (pH 7.4) with 
0.01 mM MgCl2 and 5% DMSO. The sample cell contained the aptamer solution, 
while the titrant was loaded in the syringe. In order to detect tight binding, the 
aptamer concentration was kept at 20 μM while the titrant (cocaine or ATMND) 
concentration was 500 μM. We introduced 19 total injections of 2 μL each and a 
purge injection of 0.4 μL. The purge injection was not included in the calculations. 
Two sets of each experiment with cocaine or ATMND were performed at 25 °C. 
The raw data were averaged and fitted to the two sets of sites and single-site 
binding models and adjusted for the heat of the titrant. 
3.3.3 Detection of Cocaine in Urine, Serum, and Saliva 
 
Different concentrations of biofluids were obtained by dilution with deionized water. 
To test the quenching effect of biofluids, we mixed ATMND (500 nM) in 2× reaction 
buffer (20 mM Tris, 0.02 mM MgCl2, pH 7.4) with an equal volume of biofluids, 
followed by fluorescence measurements. To test the signal gain of cocaine in 
different biofluid dilutions, we spiked cocaine (500 μM) into 50%, 25%, 10%, 5%, 
and 0% urine, serum, and saliva. These were then mixed with an equal volume of 
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2× reaction buffer containing ATMND (500 nM) and 38-GC (4 μM), followed by 
subsequent fluorescence recording. To perform cocaine detection in biofluids, 
different cocaine concentrations were spiked into 5% urine, 5% serum, or 10% 
saliva. Equal volumes of cocaine-spiked biofluids and 2× reaction buffer containing 
ATMND (500 nM) and 38-GC (4 μM) were mixed to read the fluorescence. Unless 
otherwise indicated, fluorescence measurements were obtained with excitation at 
358 nm and emission at 405 nm. 
3.4 Results and discussion 
 
We devised our platform based on cocaine-mediated displacement, employing an 
aptamer sensor that reports the presence of cocaine via the displacement and 
unquenching of a bound fluorophore molecule. In the absence of ligand, the 
cocaine binding aptamer forms three helical stems around a three-way junction. 
ATMND binds the aptamer at this junction, which results in the quenching of its 
fluorescence (Figure 3B). Since this aptamer also binds cocaine, the competitive 
binding of cocaine results in a rapid displacement of the ATMND from the aptamer. 
The released ATMND generates a high-intensity fluorescent signal, reporting the 
cocaine-binding event. 
To develop a cocaine displacement-based sensor platform, we need a signal 
reporter which binds to the cocaine-binding aptamer but can also be displaced by 
cocaine, reporting the presence of the target. We recently discovered that the 
MNS-4.1 cocaine binding aptamer can also bind to the fluorophore ATMND and 
the cocaine binding can competitively displace ATMND from the aptamer–dye 
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complex. Free ATMND is highly fluorescent in buffer, but ATMND is rapidly bound 
by MNS-4.1 upon addition of the aptamer, and we observed that ATMND 
fluorescence was greatly quenched within seconds. When we incubated 250 nM 
ATMND with 2 μM MNS-4.1, roughly 93% of the fluorescent signal was quenched, 
with the remaining 7% contributing to the low level of fluorescence background 
(Figure 4A). The aptamer–ATMND complex is very stable, and we did not observe 
any detectable fluorescence change over the course of 1 hour. We characterized 
sensor performance in terms of signal gain, which is the ratio of the background- 
subtracted fluorescence obtained with cocaine relative to that obtained in the 
absence of cocaine, such that a larger signal gain is indicative of better sensitivity. 
The addition of cocaine is predicted to trigger a conformational rearrangement in 
the aptamer (Figure 3B), with two adjacent GA base pairs and a dinucleotide bulge 
(T20 and C21) within the aptamer binding pocket.62 Upon 50 μM cocaine addition, 
we observed a competitive target binding to MNS-4.1, resulting in successful 
displacement of ATMND from the aptamer with a signal gain of 9.6 (Figure 4A). 
This fluorescence increase was stable for at least several hours (data not shown). 
We assume that this competitive binding results from a pure site-to-site 
displacement, although it could also be explained by a heterotropic allosteric effect. 
In contrast, we observed no measurable signal change in the absence of cocaine 
(Figure 4A). 
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Figure 4. Our aptamer-based sensor rapidly responds in the presence of cocaine. 
(A) Time course of ATMND release. ATMND in buffer is highly fluorescent when 
excited at 358 nm. ATMND is rapidly bound upon addition of the cocaine-binding 
aptamer, resulting in quenching of its fluorescence. In the presence of cocaine, the 
release of ATMND results in recovery of a strong fluorescent signal. (B) The impact 
of aptamer stability on signaling performance. The signal gain observed in the 
presence of cocaine was dependent on the composition of stem 1 and stem 3, 
which contributes to aptamer stability and ATMND/cocaine binding. Experimental 
conditions: [DNA] = 2 μM, [ATMND] = 250 nM, [cocaine] = 50 μM. Error bars 
represent the standard deviation of three measurements. 
 
Previous studies have suggested that the composition of stem 1 of the cocaine- 
binding aptamer has the greatest impact on the secondary structure of the aptamer 
as well as the target binding affinity.62 MNS-4.1 is only partially folded at 
equilibrium,60 and this is most likely due to the presence of three noncanonical 
base pairs in stem 1, which would be expected to reduce the efficiency of ATMND 
binding and quenching and thereby result in high background fluorescence. 
Neves’s group62 used 2D NMR spectral changes to confirm that the cocaine- 
binding aptamer with six Watson–Crick base pairs in stem 1 is fully folded in the 
free form and exhibits increased binding affinity as compared to the original MNS 
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4.1 aptamer. To test whether such a completely folded aptamer could reduce 
background fluorescence and boost signal gain, we engineered the 38-GT 
aptamer (Figure 3, 38-GT) by converting the three putative noncanonical base 
pairs in stem 1 to Watson–Crick base pairs, forming a seven-base-pair stem. 
Additionally, we tested whether decreasing the length of the stem would result in 
destabilization of the aptamer structure and studied the effects of such nucleotide 
deletions to the sensor performance. Interestingly, increasing the length of the 
stabilizing stem led to higher fluorescence quenching of a constant concentration 
of ATMND with little quenching being observed with an aptamer sequence with a 
short (3-base pair) stem 1 (Figure 5). These results suggest that binding of ATMND 
requires formation of the hydrophobic three-way junction pocket that can host the 
ATMND fluorophore, with increasing folding of the aptamer resulting in better 
binding of ATMND. The 38-GT (seven base-pairs in stem 1) resulted in reduced 
background fluorescence, with 95% ATMND quenched (data not shown), 
indicating that ATMND binds tightly to 38-GT. We did not observe any loss of 
cocaine-displaced signal and obtained an increased signal gain of 12 in the 
presence of 50 μM cocaine (Figure 4B). To further reduce the background signal, 
we subsequently converted the G–T wobble pair in stem 3 of 38-GT to a matched 
G–C base pair (Figure 3, 38-GC). This increased structural stability led to a further 
increase of ATMND quenching efficiency (97%) and an improved signal gain of 17 
(Figure 4B) with 50 μM cocaine. 
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Figure 5. Stem-length effects on fluorophore binding and displacement by 
cocaine. 
Various aptamer sequences were studied with increasing length of the structure 
stabilizing stem 1 from three base-pairs to seven base-pairs. Additionally, a seven 
base-pair sequence was further mutated by changing a non-match base-pair in 
stem 3 to a fully matched Watson-crick helix (termed 38-GC). Increasing the length 
of the stabilizing stem led to higher fluorescence quenching of a constant 
concentration of ATMND suggesting that formation of the three-way junction is 
necessary for binding of ATMND to the aptamer structure. The highest fluorescent 
quenching was observed with the 38-GC sequence which has the most stable and 
folded structure. [DNA] = 2 µM, [ATMND] = 250 nM, Ex: 358 nm; Em: 405 nm. 
 
We presume that the greatly enhanced stability of 38-GC contributes to its high 
affinity toward both ligands, favoring formation of stable aptamer–ligand 
complexes and resulting in low background and high target-displaced signal gain. 
We used isothermal titration calorimetry (ITC) to investigate the binding affinity and 
thermodynamics of MNS-4.1, 38-GT, and 38-GC with regards to both ATMND and 
cocaine. The results confirmed that the aptamers bind both molecules, and that 
binding in both cases is enthalpically driven and entropically unfavorable (Table 
1). ITC stoichiometry data indicated that each aptamer binds to one cocaine 
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molecule or two ATMND molecules. After correction of the dilution heat, we used 
the single-site binding model to obtain equilibrium dissociation constants (Kdc) of 
6.7 ± 1.3 μM (Figure 6A), 10 ± 1 μM (Figure 6C) for cocaine binding to MNS-4.1 
and 38-GT, respectively. Interestingly, affinity for cocaine is essentially unchanged 
even after stabilization of the aptamer structure with completely matched helix in 
stem 1. We used the two sets of sites binding model to obtain affinity 
measurements for ATMND binding sites on MNS-4.1 (Kd1, 6.6 ± 0.8 μM; Kd2, 25 ± 
1 μM) (Figure 6B) and 38-GT (Kd1, 0.16 ± 0.08 μM; Kd2, 6.3 ± 1.2 μM) (Figure 6D). 
In contrast to cocaine binding, ATMND affinity increases substantially after 
substitution of the mismatched base-pairs in stem 1 with a completely matched 
helix. Accordingly, the higher levels of fluorescence quenching are observed 
presumably because of the higher affinity of ATMND to the more stable fully 
matched helix as observed from the fluorescence experiments. ITC data also 
showed that the G–C change in 38-GC further increases the stability of the 
aptamer, leading to increased binding affinity for both ligands. Compared with 38- 
GT, we observed 4-fold enhanced binding to cocaine (Kdc = 2.6 ± 1.0 μM) and 10- 
fold tighter binding to ATMND (Kd1 = 0.016 ± 0.001 μM; Kd2 = 2.6 ± 1.0 μM) (Figure 
7). The thermodynamics of binding indicate that the binding of both molecules is 
highly enthalpically driven. This suggests strong hydrogen bonding interactions 
upon binding of both molecules. Interestingly, cocaine binding results in higher 
levels of enthalpy change. This is presumably because cocaine binding can induce 
changes in the aptamer conformation, resulting in creation of new hydrogen bonds. 
Unlike cocaine, ATMND does not affect the structure of the aptamer, but rather 
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might just reside in the 3-way junction pocket of the host aptamer and hydrogen 
bond with unpaired nucleotides in the absence of cocaine. 
 
Table 1. Binding and thermodynamic parameters of 38-GT and 38-GC for ATMND 
and cocaine* 
 
*Data obtained at 25°C in 10 mM Tris (pH 7.4) + 0.01 mM MgCl2 + 5% DMSO. The 
values reported are averages of three individual experiments with one standard 
deviation. 
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Figure 6. ITC data demonstrated that MNS-4.1 and 38-GT binds both cocaine and 
ATMND. 
ITC data showing heat generated from each injection of (A) cocaine or (B) ATMND 
into the MNS-4.1 aptamer solution. (C, D) ITC data showing heat generated from 
each injection and integrated heat plot of (C) cocaine or (D) ATMND into the 38- 
GT aptamer solution. Experimental conditions: [MNS-4.1 or 38-GT] = 20 µM, 
[ATMND] = 500 µM and [cocaine] = 500 µM. Binding experiments were performed 
in 10 mM Tris (pH 7.4) including 0.01 mM MgCl2 and 5% DMSO at 25 °C. 
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Figure 7. 38-GC binds both cocaine and ATMND. 
(Top) ITC data showing heat generated from each injection of (A) cocaine or (B) 
ATMND into the 38-GC solution. (Bottom) The integrated heat plot after correcting 
for the heat of dilution. Experimental conditions: [38-GC] = 20 μM, [ATMND] = 500 
μM, and [cocaine] = 500 μM. 
 
These results demonstrate the potential of ATMND as an excellent transduction 
element; its tight binding to the aptamer results in a very low background signal 
until it becomes displaced via competitive binding of cocaine, with incredibly fast 
recovery of its fluorescence (i.e., seconds). To minimize the background signal and 
obtain a high signal-to-noise ratio, we used a fixed concentration of 38-GC (2 μM) 
to optimize the concentration of ATMND and thus obtained an optimized 38- 
GC:ATMND ratio of 8:1 (Figure 8); under these conditions, we calculated that 
99.3% dye–aptamer complexes contained only one ATMND molecule bound at 
48  
the strong binding site, while the concentration of complexes containing two 
ATMND molecules was sufficiently low as to be negligible (see modeling 
calculations). 
 
Figure 8. Effect of different concentrations of ATMND on fluorescence signal gain. 
Maximum signal gain was achieved at an optimized molar ratio between the 38- 
GC aptamer and ATMND of 8:1. [38-GC] = 2 µM, [cocaine] = 50 µM, with excitation 
at 358 nm and emission at 405 nm. 
 
3.4.1 Modeling data for binding of ATMND to 38-GC: 
 
Two assumptions are required for the calculation 
 
1. One DNA aptamer molecule can bind one or two ATMND molecules in its 
hydrophobic pocket; 
2. Two ATMND molecules can occupy the hydrophobic binding pocket 
independently 
In the presence of ATMND, a DNA aptamer molecule can bind a single ATMND 
molecule strongly at site 1 to form complex 1 or it can bind one ATMND molecule 
weakly at site 2 to form complex 2, establishing two equilibriums in the solution: 
49  
Site 1 (strong binding): 
 
1/Kd1 
DNA + ATMND  Complex 1 
Kd1 
 
 
(I) 
 
 
Site 2 (weak binding) 
 
1/Kd2 
DNA + ATMND  Complex 2 
Kd2 
 
 
(II) 
 
 
There is also a possibility for complex 1 to bind a second ATMND molecule weakly 
or for complex 2 to bind a second ATMND molecule strongly. Thus, another two 
related equilibriums are formed independently: 
 
Complex 1 + ATMND 
 
 
 
 
Complex 2 + ATMND 
1/Kd2 
Kd2 
1/Kd1 
Kd1 
 
Complex 3 
 
 
 
 
Complex 3 
 
(Kd1 and Kd2 stand for the dissociation constant between the ATMND molecule and 
the DNA aptamer at its strong binding site or its weak-binding site, respectively.) 
The dissociation constant for reactions (I-IV) can then be defined in terms of the 
equilibrium concentration of each component: 
(III) 
 
 
(IV) 
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[𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷][𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷] 
𝐾𝐾𝐾𝐾𝑑𝑑𝑑𝑑1  = [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] (1) 
[𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷][𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷] 
𝐾𝐾𝐾𝐾𝑑𝑑𝑑𝑑2  = [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2]  (2) 
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1][𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷] 
𝐾𝐾𝐾𝐾𝑑𝑑𝑑𝑑2  = [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3]  (3) 
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2][𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷] 
𝐾𝐾𝐾𝐾𝑑𝑑𝑑𝑑1  = [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3]  (4) 
 
 
By using equation (1) to divide equation (2), we deduce equation (5): 
 
 [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2] 𝐾𝐾𝐾𝐾𝑑𝑑𝑑𝑑1 = [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] 𝐾𝐾𝐾𝐾𝑑𝑑𝑑𝑑2 (5) 
 
Equation (6) can be deduced from equations (2) and (3), 
 
 [𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷][𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3] [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2][𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] = 1 (6) 
 
 
Thus, 
 
 [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3] = [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2]  [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] [𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷]  
ATMND is not completely consumed in the reaction due to the equilibrium; 
therefore a comparison can be successfully made between the equilibrium 
concentration of ATMND and DNA and their total concentration (denoted as 
ATMNDT and DNAT) 
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[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] 𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝑇𝑇𝑇𝑇 0.25 𝑢𝑢𝑢𝑢𝐴𝐴𝐴𝐴 1 < = = [𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷] 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝑇𝑇𝑇𝑇  − 𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝑇𝑇𝑇𝑇 2 𝑢𝑢𝑢𝑢𝐴𝐴𝐴𝐴 − 0.25 𝑢𝑢𝑢𝑢𝐴𝐴𝐴𝐴 7 (7) 
 
Equation (6) can be recalculated using the solution from equation (7) to obtain the 
comparison of the equilibrium concentration between complex 2 and complex 3: 
 
 [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3] < 1 [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2] 7  
Based on ITC data, the values of dissociation constants (Kd1 and Kd2) of ATMND 
to 38-GC are 0.016 uM and 2.6 uM, respectively. Thus, a relationship between the 
concentration of the three complexes is established as follows: 
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] = 162.5[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2] > 1137.5[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3]  
Thus, the percentage of complex 1: 
 [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] + [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2] + [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3]  = [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶 1] 1 [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶 2] [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶 3] > 1       1    1  [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] + [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] + [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] 1 + 162.5 + 1187.5  = 99.3%  
Since 99.3% of the ATMND-aptamer complex is complex 1 in which the aptamer 
only bind one ATMND at the strong site, we have ignored the formation of complex 
and complex 3 in the reaction. 
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3.4.2 Mutation of binding pocket nucleotides 
 
Our sensor is modeled on the understanding that both ATMND and cocaine 
compete for the same aptamer, and we assume that the binding site of both ligands 
is located within the hydrophobic three-way junction pocket. To confirm this 
assumption, we examined the extent to which targeted nucleotide changes affects 
ligand binding and target competition. We designed mutants of 38-GC in which we 
introduced a nucleotide switch between T20 and C21 (38-GC-M1; Figure 9) or a 
replacement of thymine at position 20 with an adenine (38-GC-M2; Figure 9). 
Previous publications have determined that such mutations eliminate binding 
affinity for cocaine. We tested these mutant aptamers in our competitive cocaine- 
binding fluorescence assay and observed significantly reduced binding to both 
ATMND and cocaine, with a high fluorescence background and a low cocaine- 
displaced fluorescence recovery (Figure 9). This poor ATMND binding and weak 
cocaine displacement resulted in a signal gain of just 1.3 and 1.2 with 50 μM 
cocaine for 38-GC-M1 and 38-GC-M2, respectively. This very weak binding affinity 
of mutant aptamers to both ATMND and cocaine was also confirmed by ITC 
(Figure 10). The enthalpy change in the binding interaction of both ATMND and 
cocaine with the mutated aptamers was much smaller, suggesting inhibition of 
hydrogen bonding. This is consistent with previous studies showing that mutations 
to nucleotides that contribute to formation of this hydrophobic pocket, including the 
unpaired T20 and C21, can profoundly alter the aptamer’s binding affinity for 
cocaine.149 
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Our mutation experiments indicate that ATMND binding is also heavily dependent 
on C21 and T20. Nakatani et al.150,151 used 15N NMR experiments to reveal that 
1,8-naphthridine selectively binds to cytosine or thymine via a three-point hydrogen 
bond152 and that the binding affinity of ATMND to various target nucleotides is as 
follows: cytosine > thymine > adenine > guanine.66 Thus, it is likely that ATMND 
binds either C21 or T20 within the three-way junction of the aptamer through a 
three-point hydrogen bond.153,154 Additionally, we observed a large negative 
enthalpy change in ITC experiments, which also indicates the formation of 
hydrogen bonds between ATMND and the aptamer. We believe that ATMND forms 
these hydrogen bonds and possibly cooperates with adjacent nucleotides via π- 
stacking interaction to significantly quench its fluorescence (figure 11).153–156 
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Figure 9. (A-D) Modifications of the 38-GT aptamer. Convert a GT base-pairing to 
a GC base-pairing in stem 3 (B) further increases its ligand binding affinity, 
whereas mutations in the binding pocket (C, D) reduce ligand affinity. (E) Mutations 
to the unpaired bases in the hydrophobic binding pocket of 38-GC alter ATMND 
binding and cocaine detection. Both the 38GC-M1 and 38-GC-M2 mutants 
exhibited decreased quenching efficiency and cocaine-displaced signal gain. (F) 
A fluorescence binding assay shows the differences in signal gain for these various 
38-GT derivatives in the presence of 50 µM cocaine. Experimental conditions: 
[DNA] = 2 µM, [ATMND] = 250 nM. Error bars represent the standard deviation of 
three measurements. 
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Figure 10. 38-GC-M1 and 38-GC-M2 demonstrated a very weak binding affinity 
for ATMND and cocaine. 
(A, B) ITC data showing heat generated from each injection and integrated heat 
plot of (A) cocaine or (B) ATMND into the 38-GC-M1 aptamer solution. (C, D) ITC 
data showing heat generated from each injection and integrated heat plot of (C) 
cocaine or (D) ATMND into the 38-GC-M2 aptamer solution. Experimental 
conditions: [38-GC-M1/M2] = 20 µM, [ATMND] = 500 µM and [cocaine] = 500 µM. 
Binding experiments were performed in 10 mM Tris (pH 7.4) including 0.01 mM 
MgCl2 and 5% DMSO at 25 °C. 
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Figure 11. Binding of ATMND to the cocaine aptamer. 
Mutational studies and isothermal titration calorimetry indicate that formation of the 
three-way junction structure and the cytosine at position 20 are highly important 
for binding of ATMND. Thus, we propose that ATMND possibly binds at this site 
thru hydrogen bonding as it can be protonated in solution. ITC experiments exhibit 
large enthalpy changes which suggest formation of such hydrogen bonds. Binding 
of ATMND is essentially eliminated upon mutation of the C20 nucleotide, 
suggesting a possible binding site for ATMND. 
 
Our sensor is based on a simple, one-pot, one-step reaction that entails the simple 
mixing of 38-GC, ATMND, and cocaine at room temperature and then exploiting 
the rapid competition between cocaine and ATMND for limited aptamer binding 
sites to quantitatively detect cocaine in samples. We observed that the signal gain 
increased with cocaine concentration, reaching a saturated signal gain of 19 with 
250 μM cocaine (Figure 12A), with a linear range of 0–8 μM (Figure 12A, inset). 
The low background resulting from the high affinity interaction of 38-GC with 
ATMND yields an excellent limit of detection (LOD). In a reaction with 2 μM 38-GC 
and 250 nM ATMND, we achieved an LOD of 200 nM within 20 s, more than 50- 
fold better than most existing aptamer-based systems59,63,64,142,148,157 and 
comparable to sensitive assays that require enzymatic amplification (Table 2). The 
LOD was calculated as S/N > 3, where the noise was a drug-free sample and the 
minimum amount of sample was 3 times this amount. 
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Figure 12. Sensitivity and specificity of the ATMND-based sensor in the reaction 
buffer. 
(A) Calibration curve shows a strong concentration-dependent response to 
cocaine by 38-GC-ATMND. (B) Our sensor specifically responds to cocaine but 
exhibits almost no response to its major metabolite benzoylecgonine. 
Experimental conditions: [DNA] = 2 μM, [ATMND] = 250 nM. Error bars in plot A 
represent the standard deviation of three measurements conducted at each 
cocaine concentration. 
 
Table 2. Comparison of aptamer-based sensors for cocaine detection 
 
 
 
The 38-GC-ATMND complex offers a superior signal transduction mechanism for 
immediate and specific cocaine detection with a robust signal gain. Since Cy7 has 
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been used as a signal reporter in a previously reported cocaine-mediated aptamer- 
based assay,60 we compared the sensor performance of 38-GC with either Cy7 or 
ATMND under optimized conditions and confirmed that 38-GC exhibits a much 
better signal gain and sensitivity with ATMND. For example, our ATMND-based 
“signal-on” sensor produces an approximate signal gain of 17 with only 1.5% of 
relative standard deviation (RSD) in the presence of 50 μM cocaine (Figure 12A), 
while the same cocaine concentration produces only a 35% signal decrease with 
5% of RSD for the Cy7-based “signal-off” sensor (Figure 13). 
 
 
Figure 13. Calibration curve for a 38-GC-Cy7-based sensor. 
Experimental conditions: [38-GC] = 2 µM, [Cy7] = 7 µM. Error bars represent the 
standard deviation of three measurements conducted at each cocaine 
concentration. Relative sensor response in terms of percent change is shown, 
because this is more reproducible than absolute absorbance values. The signal 
gain is calculated as [(Abscocaine-Cy7 - Absbackground) / (AbsCy7 - Absbackground)] × 100% 
where the background is derived from buffer and absorbance was measured at 
760 nm. 
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Cocaine-binding aptamers generally exhibit good specificity in terms of 
distinguishing cocaine from structurally similar major metabolites.57 We tested the 
specificity of our assay with benzoylecgonine, which is the corresponding 
carboxylic acid derivative of cocaine with an otherwise almost identical 
structure.158,159 Relative to the signal gain of 17 obtained with 50 μM cocaine, we 
did not detect a measurable signal change upon addition of 50 μM 
benzoylecgonine and observed a signal gain of just 1.7 when we increased the 
benzoylecgonine concentration to 1 mM (Figure 12B), which is consistent with the 
good specificity observed with previous aptamer-based sensors (Table 2). 
Additionally, we tested several other compounds for cross-reactivity with our 
sensing method, including cocaethylene (biomarker of alcohol and cocaine 
consumption), diphenhydramine (allergy medicine and cutting agent), cocaine 
metabolites and cutting agents in street drugs. Several of these compounds do 
not result in any measurable signal increase, however we did notice some cross- 
reactivity with the cocaine metabolite cocaethylene and the drugs 
diphenhydramine and promazine (Figure 14). Cross-reactivity with cocaethylene 
would allow for detection of co-consumption of alcohol and cocaine while cross- 
reactivity with over the counter drugs such as diphenhydramine might be 
problematic in instances where they are being consumed as medicine or are 
present as cutting agents in street samples. Wang et al. detailed a method that 
can be used to increase the specificity for the same cross-reactive molecules by 
utilizing an enzyme-based detection method.110 
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Figure 14. Cross-reactivity of the ATMND-sensor for several compounds of 
interest in cocaine measurements. 
Cocaethyelene metabolite was found to bind to the aptamer and result in increased 
fluorescence as well as diphenhydramine (allergy medicine) and promazine 
(antipsychotic). The cutting agent scopolamine does not result in any interference. 
 
The average concentration of cocaine in different body fluids within 24 h after 
ingestion is typically greatest in the urine (milligrams per liter), with lower 
concentrations found in saliva and serum, respectively.56 We explored the 
practicality of our assay for performing cocaine detection in different body fluids 
collected from healthy donors. We first tested our assay with 250 μM cocaine 
spiked into various dilutions of urine, saliva, or serum (Figure 15) samples. We 
observed that the signal gain increased in inverse proportion to the biofluid 
concentration, with a maximum signal gain of 8.2, 9.6, and 5.6 for 2.5% urine, 
saliva, and serum, respectively. Human urine normally contains very small 
amounts of protein (<0.14 mg/mL)160 and a large number of fluorescent 
metabolites.161,162 We observed that urine samples indeed generated a strong 
background fluorescence at 400–550 nm (Figures 16 and 17) and metabolites 
such as pterins, flavins, porphyrins, and 4-pyridoxic acid may be contributing to 
this  fluorescence.163   Although  the  urine  matrix  exhibited  a  high  background 
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fluorescence, we still achieved successful detection of cocaine. We observed that 
the signal gain increased with increasing cocaine concentrations, with an LOD of 
460 nM cocaine in 2.5% urine (Figure 18A). 
 
 
Figure 15. Successful detection of cocaine spiked into different dilutions of urine, 
saliva and serum with 38-GCATMND. 
Signal gain decreases with increasing concentrations of urine. Experimental 
conditions: [38-GC] = 2 µM, [ATMND] = 250 nM and [cocaine] = 250 µM, with 
excitation at 358 nm and emission at 405 nm. Error bars represent the standard 
deviation of three measurements. The signal gain is calculated as (Fcocaine-ATMND - 
Fbackground) / (FATMND - Fbackground) where the background is derived from the biofluid 
sample. 
 
 
 
Figure 16. 5% urine and serum samples emit fluorescence within the wavelength 
range from 375 nm to 600 nm when excited at 358 nm. 
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Figure 17. Fluorescence intensities for different concentrations of various 
biofluids. 
Serum and urine both generate high fluorescence, which increases with the 
increase of concentration. In contrast, saliva emits no fluorescence. Excitation 
wavelength: 358 nm, and emission wavelength: 405 nm. 
 
Figure 18. Calibration curves for ATMND-38-GC-displaced cocaine detection in 
biological samples. 
We observed a strong concentration-dependent response to cocaine in (A) 2.5% 
urine and in (B) 5% saliva. Experimental conditions: [DNA] = 2 μM, [ATMND] = 250 
nM. Error bars represent the standard deviation of three measurements conducted 
at each cocaine concentration. 
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Serum samples generate weak background fluorescence (Figures 16 and 17). 
However, since serum contains ∼67 mg/mL protein,164 which might bind ATMND 
molecules within hydrophobic patches and thereby quench its fluorescence 
(Figure 19), we expected these samples to be significantly challenging to work 
with. Even though serum samples demonstrated considerable ATMND quenching 
at 405 nm (Figure 19), we were still able to detect cocaine in 2.5% serum with a 
detection limit of 900 nM (Figure 20). Saliva is a cleaner matrix with no background 
fluorescence (Figure 17), containing only ∼1.6 mg/mL proteins,165 and we were 
thus able to use 5% saliva to achieve cocaine detection and establish a calibration 
curve with an LOD of 520 nM (Figure 18B). Based on these findings, we calculated 
detection limits of 10.4, 18.4, and 36 μM in undiluted saliva, urine, and serum, 
respectively. These experiments successfully demonstrate the feasibility of using 
our sensor to detect cocaine in body fluids. 
 
 
Figure 19. Fluorescence intensities of ATMND in different concentrations of saliva 
and serum. 
The fluorescence of ATMND was quenched by higher concentrations of saliva and 
serum. Excitation wavelength: 358 nm, and emission wavelength: 405 nm. 
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Figure 20. Calibration curves for cocaine detection with ATMND-38-GC in 2.5% 
serum. 
(A) Concentration–dependent response of signal gain to cocaine concentration. 
(B) Linear relationship between signal gain and cocaine concentration within the 
range from 0 to 8 µM. Experimental conditions: [38-GC] = 2 µM, [ATMND] = 250 
nM, with excitation at 358 nm and emission at 405 nm. Error bars represent the 
standard deviation of three measurements conducted at each cocaine 
concentration. 
 
3.4.3 Detection in alcoholic and soft drinks 
 
We further used the ATMND-cocaine test to measure cocaine in drinks such as 
beer and soda. Detection was performed in 10% diluted solutions with spiked 
cocaine (250 uM). Detection in several soft drinks proved difficult because of 
intense background fluorescence, however detection was still possible in drinks 
such as tea, Coca-Cola and soda (Figure 21). Detection of spike cocaine was also 
tested in alcoholic drinks. Several alcoholic drinks resulted in unreliable detection 
because of high background fluorescence even in the absence of cocaine. 
Detection was still possible in several diluted alcoholic drinks (Figure 22). The 
outlined method thus can successfully detect cocaine in spiked drinks, however 
care should be taken to examine the background fluorescence of the matrix. 
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Figure 21. Detection of cocaine in spiked soft drinks. 
(A) fluorescence intensity of ATMND in soda solution. Addition of cocaine results 
in a significant fluorescence increase because of the spiked cocaine in the solution. 
(B) Different soft drinks were tested with only Gatorade resulting in unreliable 
detection of cocaine. [DNA] = 2 uM, [ATMND] = 250 nM, [COC] = 250 uM, Ex: 358 
nm, Em: 405 nm. 
 
 
 
Figure 22. Detection of cocaine in alcoholic drinks. 
Several drinks were diluted to 10% and spiked with cocaine. Detection was 
performed with the ATMND-method resulting in correct detection for several 
drinks. However, several drinks exhibit intense fluorescence that results in 
unreliable results. Care should be taken to examine the fluorescence signature in 
a case by case basis. [DNA] = 2 uM, [ATMND] = 250 nM, [COC] = 250 uM, Ex: 
358 nm, Em: 405 nm. 
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3.5 Conclusion 
 
We have demonstrated the rapid, sensitive, and specific detection of cocaine 
based on competitive aptamer binding between the cocaine target and the ATMND 
fluorescent signal reporter. Our 38-GC aptamer is derived from the previously 
reported MNS-4.1 aptamer and incorporates additional complementary base pairs 
at multiple sites that stabilize aptamer folding and thereby increase binding affinity 
to both ligands and reduce background fluorescence. ATMND fluorescence is 
significantly quenched upon binding to 38-GC. In the presence of cocaine, 
however, ATMND is displaced from the dye–aptamer complex, generating an 
intense fluorescence signal. We confirmed the competitive binding of the two 
ligands to the 38-GC and demonstrated that targeted mutagenesis clearly affects 
sensor performance. 
Our assay is remarkably simple, fast, and specific. Detection is performed in a 
single tube containing the 38-GC-ATMND complex and the sample of interest. The 
assay is label-free, and detection only requires 20 s at room temperature to 
achieve a linear range of 0–8 μM with an LOD of 200 nM in buffer, about 50-fold 
lower than assays based on target-induced conformational change.11,57,59,64,140–144 
More importantly, our assay can achieve successful cocaine detection in body 
fluids. We observed that the signal gain increased with increasing cocaine 
concentrations, obtaining LODs of 10.4, 18.4, and 36 μM in undiluted saliva, urine, 
and serum samples, respectively. After a dose of 100 mg, it is reported that cocaine 
concentration is around 2 mg/L in urine, about 3 times lower than the LOD of our 
sensor.166 Thus, a major limitation of the current assay is the interference by auto- 
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fluorescence of the biological sample which limits the sensitivity. This could be 
possibly overcome by utilizing a dye outside the 358/405 nm window. We 
anticipate that the well-established SELEX technique should likewise make it 
possible to derive similar target-ligand displacement sensors that exhibit equally 
high specificity and affinity for other small molecules. This approach therefore 
potentially offers a general framework for performing rapid and specific high- 
throughput on-site drug testing. 
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CHAPTER 4 
 
Engineering an adenosine-specific aptamer and electrochemical detection 
in undiluted serum 
A simple and specific method for the detection of adenosine is becoming 
increasingly valuable as knowledge of its modulatory function in physiology and 
pathophysiology are explicitly understood. Unfortunately, the previously reported 
Adenosine aptamer (ATP-27) cannot be utilized to measure adenosine 
concentration because of its inherent cross-reactivity to adenosine phosphate 
derivatives such as adenosine triphosphate (ATP) and adenosine diphosphate 
(ADP), which share a common core structure (ribose and adenine) and are co- 
present in biological samples. Through rational engineering of the aptamer’s 
sequence, we designed and characterized a new highly specific adenosine- 
binding aptamer which differs from ATP-27 by a single nucleotide and exhibits 
reduced cross-reactivity for ATP, ADP and adenosine monophosphate (AMP). The 
reduced cross-reactivity can be attributed to steric hindrance for negatively 
charged phosphate derivatives in the binding pocket, resulting in decreasing 
affinity as the negative phosphate charge increases, yet neutral adenosine is not 
affected. The aptamer can be modified and incorporated into an electrochemical 
aptamer-based (E-AB) platform for sensitive and specific detection of adenosine 
in buffer and undiluted serum. Sensitivity in serum is at least 40 times higher 
compared to other aptamer-based sensors but with specificity for adenosine 
against ATP, ADP and AMP that has not been previously reported in aptamer- 
based serum measurements. 
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4.1 Introduction 
 
Adenosine is an endogenous regulatory molecule with signaling function in diverse 
systems including immune and inflammation response, neuro-modulation, 
coronary blood flow and cancer pathogenesis.73,84,167 Membrane equilibration 
channels transport adenosine to the outside of the cell, however the bulk of extra- 
cellular adenosine is produced by metabolism of nucleotides (ATP, ADP and AMP) 
by membrane-bound ecto-enzymes (i.e., CD39 and CD73).123 The enzymes work 
in concert to transform ATP to adenosine, first by transformation of ATP to AMP 
by CD39 followed by metabolism of AMP to adenosine by CD73.85 Intracellularly, 
adenosine homeostasis is regulated by enzymes such as adenosine deaminase 
(ADA: transforms adenosine to Inosine) and adenosine kinase (ADK: transforms 
adenosine to AMP).168 Extracellular adenosine can regulate physiological 
functions by binding to and activating four distinct adenosine receptors (A1, A2a, 
A2b and A3) expressed in nearly all cell types.75 Physiological concentration of 
extracellular adenosine (30-300 nM) can effect regulatory functions with the high- 
affinity receptors (A1, A2a, and A3) but not with the low affinity receptor A2b.169 
Activation of the A2b receptor by adenosine requires concentrations 100 - 1,000 
times above physiological levels (>10 uM), which are only observed in pathological 
states such as hypoxia, tissue damage, cell-stress and cancer.74,76,170 Accordingly, 
adenosine measurements have been used to diagnose diseases, monitor 
therapeutic efficacy, understand the role of purinergic enzymes and adenosine 
receptors in pathophysiology, and to indirectly quantify adenosine regulatory 
enzymes and profile potential inhibitors of these enzymes.77,78,171–173 For example, 
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Corcuilo et al. proved that mice lacking the adenosine receptor A2a or the enzyme 
CD73 (transforms AMP to adenosine), spontaneously develop osteoarthritis with 
replacement of adenosine by injection preventing development of osteoarthritis in 
rats.174 Taniai et al. demonstrated higher concentrations of adenosine in the urine 
of patients suffering from metabolic disease or severe respiratory failure.171 Bimal 
et al. demonstrated elevated plasma adenosine levels during active visceral 
leishmaniasis (VL) disease and return to basal adenosine levels after successful 
treatment.172 An important aspect of these studies was utilization of a reliable 
method for adenosine measurements. Currently available methods include micro- 
dialysis, HPLC, enzyme-linked spectroscopic assays, and chromatography-MS 
based methods.77,80,82,175 These methods require complex procedures, expensive 
instruments, lengthy sample processing, and have limited temporal resolution. 
Chen et al. argued that a current challenge in therapeutic targeting of adenosine 
receptors is the unavailability of simple and direct adenosine sensors.75 
Various groups have attempted to develop simple sensing methods to measure 
adenosine concentrations with high specificity. Ahn et al. developed a chemical 
method that indirectly measured adenosine by employing s- 
adenosylhomocysteine-hydrolase to transform s-adenosylhomocysteine to 
homocysteine and adenosine. Homocysteine results in fluorescence quenching of 
a silver nanocluster and exogenous adenosine is indirectly measured as it inhibits 
the enzymatic reaction of s-adenosylhomocysteine-hydrolase preventing 
production of the homocysteine which regulates the fluorescence output. The 
method showed great specificity against ATP and ADP in 5% diluted complex 
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samples, however the method was not tested in undiluted serum.176 Additionally, 
the method requires exogenous reagents and time-consuming enzymatic 
reactions which limit the temporal resolution.177 Biovision has a commercially 
available fluorescence kit for indirect detection of adenosine in serum and urine. 
Biovision’s method relies on transformation of adenosine by adenosine deaminase 
to inosine and a downstream enzymatic transformation (not publicly available) of 
the resulting product for fluorescence detection.178 While highly sensitive, the 
method is not highly specific, with intense background interference from 
endogenous inosine and xanthine, molecules which are commonly present in 
biological samples.179 Other methods have also been developed based on enzyme 
recognition of adenosine and cascading catabolism of the target molecule to 
eventually produce hydrogen peroxide, which can be measured using 
electrochemistry or spectroscopy.81,180 Specifically for electrochemical sensors, 
enzyme immobilized electrodes require specialized and careful preparation and 
are inherently sensitive to interfering electroactive molecules in the sample solution 
because of the interrogating potential of +500 mV required for oxidation of 
hydrogen peroxide which also oxidizes molecules endogenously present in 
biological samples such as ascorbate.81,180 Specific detection of adenosine is also 
affected by inosine concentration (adenosine metabolite) which must be 
subtracted by a separate inosine reference sensor. While these methods are more 
convenient than conventional methods (e.g. HPLC), they do not measure 
adenosine directly, thus they suffer from poor specificity against matrix interferents. 
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Aptamer-based sensors are increasingly gaining popularity because of their high 
and tunable specificity, adaptability to highly selective sensing mechanisms and 
high sensitivity.9,144,181,182 Aptamers are oligonucleotide-based recognition 
molecules that can bind specific analytes such as small molecules and 
proteins.38,39 An analyte of interest, such as adenosine, is incubated with a large 
population of random and distinct oligonucleotide sequences of fixed length, 
termed a ‘library’. Distinct sequences in the library that strongly bind the analyte 
are continuously amplified (i.e., enriched) and non-binding sequences are 
discarded; this artificial evolution process (termed SELEX) is repeated until a 
unique binding sequence is isolated.39 The specificity of the isolated sequence can 
be controlled by appropriate design of the incubation and separation steps; thus 
aptamers can be made to be highly specific for a given molecule or cross-reactive 
for a family of molecules, depending on the selection conditions.139,183 
Interestingly, the previously isolated ATP-binding aptamer (herein termed ATP-27) 
is highly cross-reactive with ATP, ADP, AMP, and adenosine with little interaction 
with the mono/di/tri-phosphate portion of the adenosine molecule.47,184–187 The full 
molecular structures are presented in figure 1. Biological fluids contain mixtures of 
ATP, ADP, AMP and adenosine because of the sensitive homeostasis mechanism 
of cell energy consumption and signaling.75 Indeed, ATP is present at higher 
concentrations intracellularly (mM vs nM) and extracellularly as compared to 
adenosine, thus utilization of the current ATP-27 aptamer for specific sensing of 
adenosine is not possible.73,76 Unfortunately, most aptamer-based sensors for 
adenosine have focused on improving the sensitivity or the specificity against 
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matrix interferences, but have largely ignored the cross-reactivity problem that 
prohibits the use of the current aptamer for measurements in biological 
fluids.48,79,188 For example, time-resolved spectroscopy and flow cytometry 
aptamer-methods have achieved detection of adenosine in complex serum 
samples. However, these methods were not able to overcome the specificity 
problem of the ATP-27 aptamer and additionally sacrificed analytical performance 
with up to 10-20 times reduced binding affinity for adenosine, limiting their utility 
for clinical applications (sensitivity: 60-200 uM).46,189 Several groups have 
attempted to isolate more specific aptamers ATP, ADP and adenosine.86,190,191 For 
example, an ATP specific RNA aptamer was isolated however this aptamer 
interacts strongly with the phosphate backbone resulting in unwanted cross- 
reactivity with guanosine triphosphate (GTP).191 Stojanovic et al. reported a unique 
adenosine binding aptamer that can bind adenosine and cyclic-AMP but does not 
bind any other adenosine-phosphate derivatives.86 Unfortunately, apart from the 
selection publication there is no additional information available about this 
aptamer, characterization of its structure or its application in complex sample 
measurements. The current limitation for a functional aptamer-based sensor for 
adenosine detection is thus the inability to design a sensing platform that can 
simultaneously overcome the issues of specificity against similar molecules (i.e., 
cross-reactivity), specificity against matrix interferents and reach an appropriate 
level of sensitivity (e.g., micromolar). 
To simultaneously overcome these challenges, an adenosine-specific aptamer 
must be developed and coupled to a highly selective and highly sensitive signaling 
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mechanism. Through rational sequence engineering of the original ATP-27 
aptamer, I discovered a new oligonucleotide sequence that can specifically bind to 
adenosine and has reduced interactions with ATP, ADP and AMP. Additionally, 
the new adenosine-specific aptamer has a similar stem-loop structure as the 
original aptamer and it can be easily adapted to various signaling methods 
including electrochemistry. Electrochemical aptamer-based sensors (E-AB) can be 
utilized directly in complex samples (e.g., undiluted serum) with target-dependent 
response that is largely insensitive to interfering molecules in the matrix but whose 
cross-reactivity is characterized by the employed aptamer.93,192–194 The aptamer 
modulates the measured current by changing its conformation (i.e., secondary 
structure) upon target binding, which changes the distance and mobility of a 
covalently-attached redox molecule to the electrode surface.92,97,195,196 Signaling 
only occurs through specific target-induced changes in the aptamer’s secondary 
structure and is therefore mostly irresponsive to non-binding molecules and 
adsorption of contaminants to the electrode surface. Additionally, the scarcity of 
electroactive molecules in complex samples such as blood ensures interference- 
free detection, as opposed to optical-based sensors which suffer from significant 
interference from non-target absorbing and fluorescent molecules.176,182 Our 
method exhibits high specificity against similar molecules (e.g., vs. ATP, ADP and 
AMP), high specificity against matrix interferents even in undiluted serum and high 
sensitivity, simultaneously overcoming the limitations of current aptamer-based 
sensors for adenosine. I discuss a probable explanation for the enhanced 
specificity of the new adenosine-specific aptamer, its significance for future sensor 
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design and for the first time report an aptamer-based method for specific 
adenosine detection in undiluted serum, as evidence of its possible application in 
the medical and research fields. 
4.2 Experimental Section 
 
Reagents 
 
Adenosine, adenosine triphosphate (ATP), adenosine diphosphate (ADP), 
adenosine monophosphate (AMP) and guanosine triphosphate (GTP) were 
purchased from Sigma and dissolved to 10 - 50 mM concentration in deionized 
water (DI) and neutralized with sodium hydroxide. Approximate concentrations 
were obtained from absorption measurements at 259 nm and utilization of the 
appropriate extinction coefficient. Exonuclease I (Exo I) and Exonuclease III (Exo 
III) were purchased from New England Biolabs (NEB) and stored at -20 °C in 5 uL 
aliquots of stock solution of 100 U/µL. Oligonucleotide DNA aptamers were 
acquired from IDT DNA technologies with high-performance liquid 
chromatography (HPLC) purification in most cases except for isothermal titration 
calorimetry and circular dichroism experiments, which used standard desalted 
DNA. Methylene-blue (MB) modified DNA was purchased from Biosearch with 
HPLC purification. All DNA was dissolved using nuclease free water; the 
approximate concentration was measured at 260 nm with the corresponding 
extinction coefficient of each DNA sequence and stored at -30 °C until used. The 
DNA sequences utilized are listed in the following table: 
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Table 3. Aptamer sequences, modifications and substitutions. 
 
4.2.1 Polyacrylamide gel electrophoresis (PAGE) 
 
Denaturing polyacrylamide gel electrophoresis was utilized to determine the length 
of the DNA products of enzyme reactions. In all cases, 15% gels were used to 
provide optimal resolution and band separation. Gel preparation consisted of 
mixing 9.4 mL of 40% acrylamide solution, 5 mL of 5X Tris-Borate-EDTA (TBE), 
2.6 mL of deionized water (DI), 100 µL of freshly prepared 10% ammonium 
persulfate (APS) (w/v), and 10 µL of tetramethylethylenediamine (TEMED). Gels 
were left to polymerize for 2 hours before pre-running at 450V for 30 minutes with 
0.5X TBE running buffer. Samples were loaded at 3 µL per well (20 wells per gel). 
The running conditions were 30 mins. at 100V and 2 hours at 400V. The sample 
bands were compared to a DNA control without enzyme treatment to approximate 
the concentration of the resulting product. A marker lane was used to estimate the 
product nucleotide count. 
4.2.2 Enzyme reactions 
 
A DNA stock solution of 50 µM was heated to 95 °C and then cooled on ice for 5 
minutes. The DNA was mixed in buffer solution (10 mM Bis-tris-propane, 1 mM 
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MgCl2, 1x Bovine Serum Albumin (BSA) at pH 8.5) and the appropriate target was 
added (e.g., adenosine). The target and aptamer were incubated at 23 °C for 30 
minutes in a heating plate. Exonuclease I and exonuclease III were diluted at 
varying concentrations with 1X BSA buffer (10 mM BTP, 1x BSA at pH 8.5) unless 
otherwise indicated and were then added to the aptamer-target mixture. The 
reactions were performed at 23 °C in 200 µL PCR tubes for the time indicated. The 
reaction was stopped by mixing 5 µL of the reaction mixture with 10 µL of stop mix 
loading buffer (formamide and EDTA). 
4.2.3 Isothermal Titration Calorimetry (ITC) 
 
A Malvern ITC200 was used for the following experiments. The cell was loaded 
with the appropriate DNA sequence and the syringe was loaded with the small 
molecule ligand (e.g., adenosine). The concentration of DNA in the cell was varied 
between 15 - 30 µM to achieve sufficient heat in each injection as well as saturation 
and quality fitting curves. The syringe concentration was restricted to between 450 
- 600 µM of each small molecule attributable to significant heat of dilution being 
observed at higher concentrations. The heat of dilution from a ligand to buffer run 
was subtracted from sample runs. A general experiment consisted of a 0.4 µL 
purge injection, which was removed prior to data analysis, and 18 additional 2 µL 
injections. In cases where saturation was not achieved in a single run, the syringe 
was reloaded with ligand and a second run was performed. The data were then 
aggregated onto a single file for fitting. It is noted that the DNA used for these 
experiments was only desalted with no other purification. Accordingly, an 
estimated concentration was utilized for the data fitting, with a probable full-length 
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oligo of 80% in the overall oligo mixture according to the manufacturer, IDT DNA. 
To fit the data, we used a sequential binding model based on previous literature 
which indicate a small factor of cooperativity observed in the original ATP aptamer 
which has been characterized to have two distinct, binding sites for ATP.197,198 
4.2.4 Circular Dichroism (CD) 
 
A Jasco J-815 CD was used for these experiments. The DNA concentration was 
 
2.5 µM and the target molecule concentration was 25 µM. The target molecule 
concentration was restricted because of significant absorption of adenosine 
containing compounds at 259 nm. The aptamer solution and aptamer-target 
solutions were prepared separately and incubated at 23 °C for 30 minutes to 
maintain the same conditions as those used for enzyme reaction experiments. We 
used standard sensitivity of the instrument and scanned the spectra form 300 nm 
to 215 nm with a data pitch of 0.1 nm at 50 nm/min. The given results are the 
average of 5 scans. We monitored the scans with 3 channels: CD, HT and 
Absorbance. The background from the absorption of buffer and small molecule 
target in buffer were subtracted from aptamer-target mixtures. 
4.2.5 Aptamer immobilization to gold electrodes 
 
The gold electrodes were first polished in alumina slurry for 5 minutes and 
subsequently sonicated in deionized water and absolute ethanol for 5 minutes 
each. The electrodes were then electrochemically cleaned following the protocol 
by Xiao et al.94 First, an electrochemical reduction/oxidation cycle was performed 
in 0.5M sodium hydroxide from -0.35V to -1.35V and rescanned 1,000 times. A 
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subsequent round of oxidation/reduction steps were performed in 0.5M sulfuric 
acid (H2SO4) and a final round was performed in 0.01M potassium chloride 
(KCl/0.1M H2SO4). The working area of the electrode was determined in 0.05M 
H2SO4 by calculation of the reduction peak of gold oxide.199 The electrodes 
generally displayed a roughness ~1.1. Thiol-modified DNA was incubated with 10 
mM tris(2-carboxyethyl)phosphine (TCEP) to reduce the disulfide bond. The 
reactive thiol DNA was then diluted to 645 nM in 1x phosphate buffered saline 
(PBS) buffer. Aliquots of 200 µL of the DNA mixture were incubated with the 
cleaned electrodes for a period of 4.5 hours in the dark at room temperature. The 
modified electrodes were then backfilled with 3 mM 6-mercapto-1-hexanol (MCH), 
1 mM MCH and 1 mM dithiothreitol (DTT) or 1.5 mM DTT for 3 hours to obtain 
stable monolayers of modified aptamers. 
4.2.6 Electrochemical measurements 
 
A CHI 760 bi-potentiostat was used for all measurements. A Ag/AgCl electrode 
was used as the reference electrode and a platinum wire was used as the counter 
electrode in a three-electrode set up. Square wave voltammetry (SWV) was 
employed to monitor the current as the potential was scanned from -0.1V to -0.5V 
in 10 mM Bis-tris-propane, 50 mM NaCl buffer at pH 8.5. The frequency was set 
between 5 - 300 hertz for optimization and 100 Hz. was ultimately used as the 
optimal value. The amplitude was optimized to 25 mV and the scan rate was 1 mV. 
The signal gain was calculated as the difference in peak current in the presence 
and absence of target divided by the target-free peak current. 
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Calibration curves were collected by titrating increasing concentrations of target 
and final graphs were obtained from the average signal from at least 4 different 
electrodes in separate solutions. DNA surface coverage was measured using a 
previously reported protocol by Steel et al.200 Briefly, the modified electrodes were 
incubated in tris buffer (pH 7.4) for 30 minutes prior to measurements. A small cell 
was filled with the same buffer and degassed using argon for 10 minutes prior to 
measurements. The electrodes were then immersed in the degassed buffer 
solution while keeping the purging gas on. Chrono-coulometry was employed to 
measure the absorption of ruthenium (III) hexamine and correspondingly calculate 
the concentration of DNA molecules adsorbed onto the gold electrode surface as 
described elsewhere.200 
4.3 Results and discussion 
 
4.3.1 Cross-reactivity of the original ATP-binding aptamer 
 
Many publications have employed the 27-nt ATP-binding aptamer (herein termed 
ATP-27) to develop different, highly sensitive sensors for ATP, ADP and adenosine 
that can work in various samples matrices.184,201–203 However, in these 
publications, the inherent cross-reactivity of the ATP-27 aptamer for ATP, ADP, 
AMP and adenosine has been largely ignored or was inconsequential to the 
presented topic. I utilized the enzyme exonuclease III to probe the binding affinity 
of the various adenosine targets to the original cross-reactive ATP-27 aptamer. 
Exonuclease III has been recently reported to be inhibited by formation of aptamer- 
target complexes, generally 4-nt away from the presumed binding site.110 Thus, 
aptamer-target binding could be observed by gel electrophoresis of the enzymatic 
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reaction products. A binding aptamer would produce bright bands corresponding 
to enzymatic inhibition and non-binding sequences would display no product bands 
as the enzyme would completely degrade the aptamer structure (fig. 23a). The 
exonuclease III system requires aptamers with long stabilizing stems, thus the 
original ATP-binding aptamer (ATP-27) was extended by three additional base- 
pairs and termed ATP-33. Exonuclease III was heavily inhibited in the presence of 
binding targets, including ATP, ADP, AMP, and adenosine with retained products 
30-nt long and with concentrations of 833, 810, 276 and 548 nM, respectively (fig. 
23c). The retained product concentrations were calculated by comparison against 
the control band, which maintained a constant and known concentration. In the 
absence of target, exonuclease III displayed full activity and completely degraded 
the aptamer structure. Similar binding cross-reactivity of the ATP-27 aptamer has 
been reported with a variety of detection methods.185–187,189 A non-binding mutant 
sequence (ATP-33m) was utilized as a control with a single point mutation that 
inhibits binding to confirm that inhibition was indeed an effect of specific target 
binding and not due to enzymatic inhibition by the target itself.47 The ATP-33m 
non-binding sequence did not result in inhibition regardless of the presence or 
absence of target, which indicated that the target itself does not inhibit the enzyme 
(Fig. 23b). 
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Figure 23. Specific target binding inhibited exonuclease III digestion of the 
aptamer 4-nt away from the presumed binding site. 
(top) structure of adenosine, ATP, ADP, and AMP at pH 8.5. (a) The original ATP- 
27 aptamer was extended by addition of 3 base-pairs to the stabilizing stem and 
the extended aptamer was termed ATP-33. Specific target binding inhibits 
exonuclease III digestion, while in the absence of target the enzyme can digest the 
aptamer. (b) Exonuclease III digestion products with the ATP-33 binding aptamer 
have an estimated length of 30-nt. Only the targets which bind can inhibit the 
enzyme. A mutant non-binding aptamer (ATP-33m) was used to confirm the 
binding-induced inhibition of exonuclease III. None of the targets inhibited 
exonuclease III. (c) The band intensity was converted to a concentration value by 
comparing with the control band of constant and known concentration. The 
binding-induced inhibition resulted in DNA inhibition with products of 833, 810, 276 
and 548 nM for ATP, ADP, AMP and adenosine, respectively. 
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4.3.2 Engineering of an adenosine-specific aptamer 
 
My goal was to improve the adenosine-specificity of the ATP-27 aptamer through 
rational sequence engineering, specifically via substitution of various nucleotides 
in the target-binding domain of the aptamer. Li et al. previously noted that the ATP- 
27 cross-reactive aptamer exhibited strong binding affinity to ATP and ADP, but 
reduced binding affinity for AMP. The decreased binding affinity to AMP was 
explained by the higher negative charge on the α-phosphate of AMP (-2) as 
opposed to (-1) for ATP and ADP. The authors argued that the α-phosphate might 
have close contact and interaction with the aptamer structure, thus the increased 
negative charge of the AMP α-phosphate inhibited binding.83 We hypothesized that 
rational mutation of the nucleotides near the binding site would modulate the 
specificity of the aptamer for the various adenosine phosphate derivatives because 
of their varying size and charge (molecular structures and charge displayed in 
figure 23). Multiple nucleotides in the sequence were mutated, added or removed 
and screened for target affinity via the exonuclease III inhibition system (fig. 24a). 
Through rational mutation of the original ATP-27 aptamer sequence, we 
discovered that a single nucleotide modification of an adenine at position 23 
(counting from the 5’ end) to a thymine inhibits binding of negatively charged 
adenosine derivatives (e.g., ATP, ADP, and AMP) but maintains affinity for neutral 
adenosine (Fig. 24b). Binding of adenosine to the new adenosine-specific aptamer 
(termed Ade-33) resulted in retention of 650 nM of product while all other 
phosphate derivatives were almost fully digested (fig. 24c). A guided single-point 
mutation was introduced to the Ade-33 aptamer to obtain a non-binding control 
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sequence termed Ade-33m.47 The non-binding Ade-33m was utilized to confirm 
that enzymatic inhibition was a result of specific target-binding. Complete digestion 
occurred in the presence of all targets, further confirming the specificity of the new 
aptamer for adenosine (Fig. 24b and c). 
 
 
 
Figure 24. Exonuclease III screening test of engineered sequences and 
identification of an adenosine-specific aptamer termed Ade-33. 
(a) Structures of the original cross-reactive ATP-33 aptamer and the new 
adenosine specific Ade-33 aptamer; A single nucleotide mutation at position 23 
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(counting from the 5’ end) of A to T can modulate the specificity of the aptamer for 
specific binding of adenosine. (b) Gel electrophoresis results of exonuclease III 
reaction with a binding competent Ade-33 aptamer and a mutated non-binding 
adenosine-specific aptamer (Ade-33m). (c) Concentration measurements of 
retained product after enzymatic reaction. Binding of adenosine retains over 650 
nM of DNA product, while all other targets are almost completely digested. The 
mutated aptamer sequence is digested with all targets. 
 
4.3.3 Addition of Exonuclease I to remove background fragments 
 
Binding of the new adenosine specific aptamer can inhibit exonuclease III digestion 
but several aptamer fragments are still observed even in the absence of target or 
in experiments with a non-binding mutant. These short bands are single-stranded 
fragments without base-pairing complementary and are poor substrates for 
exonuclease III. I utilized the enzyme exonuclease I, which is highly specific for 
digestion of single-stranded DNA from the 3’ end of the DNA sequence, to remove 
the background shorter fragments. A fixed concentration of exonuclease III was 
utilized to initially digest the parent aptamer along with increasing concentrations 
of exonuclease I to determine the concentration required to digest the remaining 
non-binding fragments. Addition of 3 units of exonuclease I was sufficient to 
remove the single-stranded DNA byproducts yet retain most of the aptamer-target 
complex product with nearly 450 nM retained (fig. 25b). Interestingly, increasing 
concentrations of exonuclease I led to digestion of the 30-nt long aptamer-target 
complex, suggesting that the initial exonuclease III inhibition product is in a 
sensitive equilibrium between single- and double-stranded DNA conformations 
(fig. 25c). Next, the exonuclease I concentration was held constant and the 
exonuclease III concentration was varied to determine the minimum amount of 
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exonuclease III required to obtain the binding inhibition product. As the 
exonuclease III concentration is reduced, a different binding product is observed 
(fig. 26). From these results, it appears that exonuclease III can recognize two 
different aptamer fragments that can undergo structure-switching upon target 
binding, with lengths of 30- and 29-nt (thus termed Ade-30 and Ade-29). 
Exonuclease I is inhibited only in the presence of target because of formation of 
double-stranded DNA upon target binding (fig. 26). 
 
 
 
Figure 25. Addition of exonuclease I to remove single-stranded DNA fragments 
leftover from exonuclease III reaction. 
(a) Exonuclease III can digest the structure in the absence of binding target up to 
a point where the structure becomes highly flexible single-stranded DNA, which is 
a poor substrate for exonuclease III. Exonuclease I is highly specific for such 
single-stranded DNA structures, allowing for digestion of the leftover fragments. 
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(b) Gel electrophoresis results of increasing concentrations of exonuclease I at a 
fixed constant exonuclease III concentration. Exonuclease I can digest the leftover 
single-stranded DNA fragments, with 3 U being sufficient to easily identify the 
aptamer-target complex. (c) Graphical representation of the band intensity as 
converted into concentration by comparison with a control band of known and 
constant concentration. 
 
 
 
Figure 26. Exonuclease III can identify multiple aptamer fragments with apparent 
structure-switching functionality. 
In the absence of exonuclease III, exonuclease I does not digest the extended 
Ade-33 structure as it is double-stranded structure. Upon digestion of exonuclease 
III, two different binding fragments are produced which appear to undergo 
structure-switching upon target-binding as they are not digested by exonuclease I, 
unlike samples without target-binding which are readily digested by exonuclease 
I. 
 
4.3.4 Implications of magnesium concentration on Ade-33 specificity 
 
ATP, ADP and AMP molecules binding to the adenosine-specific aptamer 
sequence appear more susceptible to steric interactions from the substituted 
thymine at position 23. We performed the enzyme reactions with the Ade-33 
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sequence at various magnesium concentrations to test whether magnesium 
affects binding between the thymine residue at position 23 and the phosphate 
containing adenosine molecules. At high magnesium concentrations (> 5 mM), the 
retention of Ade-33 products for adenosine and ADP was <250 nM while at low 
magnesium concentrations (<5 mM) adenosine binding dominated and binding for 
ADP was severely reduced with retained products of 500 nM for adenosine and 
none for ADP (fig. 27). We conducted the same test for the original cross-reactive 
ATP-33 aptamer and observed enzyme inhibition with ADP even at magnesium 
concentrations as low as 0.25 mM (Fig. 27). Braun et al. previously demonstrated 
a similar effect of ATP binding to the cross-reactive ATP-27 aptamer at low 
magnesium concentrations.204 These results suggest that substitution of thymine 
at position 23 results in steric hindrance with the negatively charged phosphate 
groups of ATP, ADP and AMP. Thus, the Ade-33 aptamer was highly specific for 
adenosine at magnesium concentrations below 5 mM. At a concentration of 1 mM 
magnesium, the ADP retained product is 600 nM when bound to ATP-33 but no 
product is retained when incubated with the Ade-33 aptamer (fig. 27). Magnesium 
concentration above 5 mM appears to be sufficient to attenuate the steric 
hindrance and stabilize binding of the negatively charged phosphate derivatives 
with the Ade-33 aptamer.205,206 A corresponding effect was previously observed by 
Szostak et al. who noted loss of ATP binding to an RNA aptamer in the absence 
of magnesium and an increase in specificity for ATP in the presence of increasing 
magnesium concentration.191 The authors proposed a role for magnesium where 
it functions as a bridging ion between their RNA aptamer structure and the ATP α- 
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and β-phosphate groups.191 Similarly, a chemical sensor for ADP exhibits a metal- 
ion bridging mechanism which specifically binds ADP as compared to ATP and 
adenosine, by specifically targeting the phosphate groups in ADP.207 Stojanovic et 
al. previously reported a unique adenosine specific aptamer which is engineered 
to instill electrostatic hindrance between adenosine di/tri-phosphate and the DNA 
phosphate backbone, albeit with a different binding motif which only binds one 
molecule per aptamer.86 I propose that substitution of adenine with thymine at 
position 23 in the Ade-33 aptamer increases electrostatic hindrance which results 
in reduced binding to the phosphate containing adenosine derivatives ATP, ADP 
and AMP (fig. 32). It is also possible that substituting thymine for adenine reduces 
stacking interactions with neighboring bases, destabilizing the binding pocket for 
the larger ATP and ADP molecules.208 Binding of the Ade-33 aptamer with 
negatively charged ADP was independent of sodium concentration, thus it is 
presumed that the effect of magnesium is primarily as a steric shielding/bridging 
molecule and not a result of differences in the DNA backbone stability (Fig. 28). 
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Figure 27. Magnesium effect in the binding specificity of Ade-33 and ATP-33 
aptamers. (Top) The Ade-33 sequence was highly specific for Adenosine at 
magnesium concentrations below 5 mM however at magnesium concentrations 
above 5 mM, presumed shielding by magnesium allows binding of ADP with the 
concentration of the retention product comparable to adenosine. (Bottom) The 
ATP-33 aptamer did not exhibit steric hindrance as magnesium concentrations as 
low as 0.25 mM allowed for binding of ADP. The higher negative charge of ATP 
was susceptible to steric interactions but could be shielded at even 1 mM 
magnesium. 
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Figure 28. Effect of sodium on target binding. 
The binding of adenosine and ADP to the Ade-33 aptamer was independent of 
sodium concentration. This supports the hypothesis that magnesium is primarily 
useful as an electrostatic shielding molecule rather than stabilizing the aptamer 
structure. 
 
4.3.5 Probing structure-switching functionality with exonuclease I 
 
Large conformational changes between non-binding and binding competent states 
in the aptamer structure provide the largest signal gain in electrochemical aptamer- 
based sensors.48,209 While a more stable aptamer structure might have higher 
binding affinity, it will also produce a large background current because the 
aptamer will be folded even in the absence of target, bringing the redox probe close 
to the surface.48 In contrast, a destabilized aptamer will favor the non-binding state, 
reducing the background current and maximizing the signal gain upon target 
binding. I utilized the enzyme exonuclease I to test the structure-switching 
functionality of aptamer sequences. The activity of exonuclease I on the target- 
bound aptamer is inhibited because of a significant change in the conformation of 
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the aptamer from single-stranded (enzyme active) conformation to rigid double- 
stranded structure (enzyme inactive). 103,208,210 The observed inhibition products of 
the exonuclease III digestion reaction with the extended ATP-33 and Ade-33 
aptamers were ordered from IDT DNA. These fragments are 29- and 30-nt in 
length, as estimated by utilization of a molecular DNA ladder prepared in-house, 
and termed ATP-30, Ade-30, and Ade-29. An additional non-binding mutated 
sequence termed Ade-30m was also ordered with identical sequence but with a 
single-point mutation that has been shown to inhibit binding.47 All sequence 
structures are shown in figure 29. The cross-reactive ATP-30 and the new 
adenosine-specific Ade-30 sequences were first incubated with exonuclease I to 
determine the structure-switching functionality of these truncated aptamers. In the 
absence of target, exonuclease I can quickly digest the aptamer structure of both 
the ATP-30 and Ade-30 aptamers, suggesting a single-stranded conformation of 
these aptamers in the unbound state. Addition of a binding competent target 
results in inhibition of the enzyme reaction because of formation of double- 
stranded aptamer-target complexes, which are poor exonuclease I substrates. The 
ATP-30 sequence exhibited retained products with concentrations of >500 nM for 
ATP, ADP and Ade. In contrast, the Ade-30 aptamer only exhibited a retained 
product with adenosine of 550 nM, and no inhibition with ATP or ADP (fig. 29c). 
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Figure 29. Cross-reactivity testing of a new binding sequence that is specific for 
adenosine. 
(a) Aptamer products of exonuclease III inhibition-based test. The adenosine 
specific aptamer displayed two distinct products with lengths of 29- and 30-nt. (b) 
Exonuclease I-based method to identify structure-switching aptamers. The 
enzyme exonuclease I has a high degree of selectivity for single stranded 
deoxyribonucleic acid (ssDNA), preferentially hydrolyzing ss-DNA over ds-DNA.103 
Aptamer-target binding results in structural change of the aptamer conformation 
from single-stranded DNA to double-stranded DNA, thus inhibiting digestion by 
exonuclease I. (c) Various targets were incubated with the ATP-30 (original) and 
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Ade-30 (engineered) aptamer and Exo I was added. All adenosine phosphate 
derivatives bound to the cross-reactive ATP-30 aptamer resulting in inhibition 
products of the enzymatic reaction. The Ade-30 aptamer was only inhibited in the 
presence of adenosine, exhibiting improved specificity for adenosine compared to 
ATP and ADP. The inhibition product was plotted as band concentration to 
compare the apparent binding affinity to various targets. The band intensity (in nM) 
is calculated by comparison to known concentration of control sample and ladder. 
(d) The two aptamer fragments of 29- and 30-nt, were tested for structure- 
switching functionality. Both aptamers are digested by exonuclease I in the 
absence of target, suggesting a mostly single-stranded conformation in the resting 
state. Upon adenosine binding, the exonuclease I enzyme is inhibited with retained 
product concentrations of 600 nM and 350 nM for the 30-nt and 29-nt fragments, 
respectively. A mutant non-binding Ade-30m aptamer did not result in inhibition in 
the presence or absence of target. 
 
The exonuclease III reaction identifies two aptamer fragments with target-binding 
induced inhibition with lengths of 29- and 30-nt. Exonuclease I was utilized to test 
the structure-switching characteristics of these two sequences with adenosine. 
The Ade-30 aptamer results in adenosine-induced retention of nearly 600 nM of 
product while the Ade-29 aptamer only has 350 nM (fig. 29d). However, in the 
absence of adenosine the Ade-30 aptamer exhibits reduced hydrolysis, suggesting 
intermittent formation of folded structures that are poor substrates for exonuclease 
I. The Ade-29 aptamer however, is quickly digested in the absence of target, 
suggesting an equilibrium which favors the unfolded, flexible state in the target- 
free conformation (fig. 29d). 
4.3.6 Structure-switching characterization with circular dichroism 
 
Circular dichroism was utilized to further elucidate the structure-switching 
properties of the Ade-29 and Ade-30 aptamers. The Ade-29 sequence exhibited 
peaks at 240 nm and 265 nm, corresponding to B-form type DNA structures. The 
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longer Ade-30 sequence had increased ipeaks at 240 and 265 nm, corresponding 
to formation of folded DNA (Fig. 30). Addition of adenosine gave a distinct 
conformational change for the Ade-29 aptamer with increased peak height at 240 
and 265 nm corresponding to ds-DNA conformation. 16,211,212 In contrast, addition 
of adenosine to Ade-30 resulted in a less drastic shift in the conformation, possibly 
because part of the aptamer population is already in a folded conformation (fig. 
31).208 An additional control was done with the non-binding sequence Ade-30m to 
confirm the structure change was caused by target-aptamer binding and not a 
result of an artificial signal. Addition of adenosine to the Ade-30m sequence did 
not result in significant changes to the aptamer spectra (Fig. 31). 
 
 
 
Figure 30. CD spectra for Ade-29 and Ade-30 without addition of target. 
The dsDNA character was higher for Ade-30 which is expected due to its longer 
stem which stabilizes the stem-loop binding structure. 
96  
 
 
Figure 31. Test of conformational change of Ade-29, Ade-30 and Ade-30m with 
Circular Dichroism (CD). 
The highest degree of conformational change was observed for Ade-29 which 
agrees with previous reports for an ATP binding aptamer.48 A control using a non- 
binding sequence (Ade-30m) exhibited only a small change upon addition of 
adenosine which confirms that conformational change occurs only through target- 
induced aptamer folding. 
 
4.3.7 Characterization of aptamer-target binding with ITC 
 
I utilized isothermal titration calorimetry (ITC) to better understand the binding 
properties of the aptamer and the effect of magnesium concentration in relation to 
binding. It has been reported that the original ATP-27 aptamer has two binding 
sites and weak cooperativity (2 ATP molecules bind per aptamer).197,198 Based on 
these assumptions, we utilized a sequential fitting model to analyze ITC data since 
the binding sites are different and binding to one site affects the second (i.e., 
Cooperative). We first tested the binding affinity of the Ade-30 aptamer for the 
various adenosine derivatives at a low magnesium concentration (1 mM) and 
identified two adenosine molecules bind per aptamer with negative cooperativity, 
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like previously reported studies.110 Under these conditions, the binding affinity was 
strongest for adenosine and weakest for ATP with equilibrium dissociation 
constants of 8.9, 64 and 115 uM for adenosine, ADP, and ATP, respectively (fig. 
32b) which correlated well with the observed enzymatic results. However, at high 
magnesium concentration (10 mM) these effects are attenuated with similar 
binding affinity for Ade, ADP and ATP presumably due to steric shielding by 
magnesium with equilibrium dissociation constants of 9.5, 18.2, and 27.1 uM for 
adenosine, ADP and ATP, respectively (Fig. 33). For the cross-reactive ATP-30 
aptamer, strong binding of ADP and ATP targets occurred even at magnesium 
concentrations as low as 0.5 mM with dissociation constants of 2.9 and 5.0 uM for 
ADP and ATP, respectively (fig. 32b). These results suggest a possible interaction 
between the adenine at position 23 and the phosphate groups of ADP and ATP for 
stabilization instead of requirement for magnesium. We presume that the negative 
charge and size of AMP(-2), ADP (3-) and ATP (4-) play a role in the unfavorable 
binding for these molecules as compared to adenosine (neutral) at the buffer pH 
of 8.5.213 Experiments with mutant non-binding aptamer sequences (Ade-30m and 
ATP-30m) resulted in loss of binding with all the targets (data not shown). ITC and 
electrophoresis results outline the importance of magnesium to stabilize binding of 
the ADP and ATP molecules to the engineered adenosine-specific aptamer 
presumably through a bridging/shielding interaction and the ability of the Ade-30 
aptamer to bind adenosine specifically at low magnesium concentrations (fig. 32a). 
Binding of all targets resulted in a small enthalpy change upon binding of the first 
target molecule and a larger enthalpy change upon binding of the second target 
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molecule. This could be a result of the first Adenosine stabilizing the stem-loop 
structure through hydrogen bonding with a nucleotide in the aptamer sequence 
and the second adenosine further stabilizing the rest of the structure resulting in a 
zipping mechanism of the binding pocket. This correlates well with the entropy 
change which is large and negative for the second binding event, which is likely 
from a conformational change in the aptamer structure (fig. 32b). It should be noted 
that the negative entropy change was smaller for the ATP-30 sequence, 
suggesting a more stable stem structure prior to binding the second target. 
 
 
 
Figure 32. Proposed mechanism of Ade-30 specificity for Adenosine due to steric 
hinderance with ATP and ADP at low magnesium concentration. 
(table 1) ITC binding affinity measurements for adenosine, ADP, and ATP. The 
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buffer conditions were chosen to match the enzyme-based conditions. (10 mM 
BTP, 0.5-1 mM MgCl2 at pH 8.5). The DNA concentration in the cell was 20 µM 
and the concentration of small molecule in the syringe was 650 µM. A sequential 
binding model was used to fit and analyze the binding curves. 
 
Figure 33. ITC binding experiments at 10 mM magnesium for the Ade-30 
sequence. 
Under conditions of high magnesium there is significant binding for all targets 
although it appears ATP has weaker binding. This is presumably due to the steric 
shielding effect of magnesium. 
 
The Ade-29 aptamer displayed strong binding affinity for adenosine with a 
dissociation constant of 20, 131 and 173 µM for adenosine, ADP and ATP, 
respectively (fig. 34). The measured affinity was 2-fold higher for Ade-30 as 
compared to Ade-29. This is consistent with the fact that Ade-29 has an energy 
penalty to reach a binding competent state. We chose the Ade-29 aptamer to 
design a redox-modified aptamer for electrochemical sensing since it could bind to 
adenosine with relatively high affinity and maximize the signal change upon target 
binding with a large change in structure conformation. 
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Figure 34. Binding affinity of Ade-29 to adenosine, ADP and ATP under optimal 
binding conditions (10 mM BTP, 1 mM magnesium at pH 8.5). 
The binding affinity was reduced by 2-fold for all targets when compared to the 
Ade-30 aptamer. 
 
4.3.8 Design of methylene-blue modified aptamer sequence (Ade-29-MB) 
 
In blood or serum, spectroscopic methods are seldom utilized because of 
significant interference from the matrix complicating sensitive measurements in 
undiluted samples.176,193 Therefore, I adapted the Ade-29 aptamer for 
electrochemical sensing which is both sensitive and highly selective, readily 
applicable for detection in undiluted complex samples.10 Electrochemical aptamer- 
based signaling is a result of specific target-induced changes in the conformation 
of an aptamer immobilized to an electrode surface and covalently labeled with an 
electroactive molecule, producing a current change that corresponds to target 
concentration.192,214,215 The redox molecule methylene blue was covalently- 
attached to the 3’ end of the Ade-29 aptamer while the 5’ end was chemically 
modified with an alkane thiol. To ensure close contact between the methylene blue 
and electrode surface, the Ade-29-MB aptamer was modified with three additional 
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thymine residues at the 3’ end to match the non-binding residues at the 5’ end that 
are conserved from the previous enzymatic experiments (fig. 35). In the absence 
of target, the Ade-29-MB structure is flexible, placing the redox tag away from the 
electrode and inhibiting electron transport. Target-induced changes in the structure 
result in folding of the aptamer, bringing the redox tag in proximity to the electrode 
surface and increasing the measured current. The advantages of this platform is 
that it enables sensitive sensors with large signal gain, provides a large degree of 
selectivity because only the aptamer redox element is active in the potential 
window employed and is indifferent to non-specific binders or contaminants that 
might absorb on the electrode surface.181,215 
 
 
 
Figure 35. Design of methylene blue modified adenosine aptamer sequence: Ade- 
29-MB. 
The aptamer is functionalized with a thiol group on the 5’ end to immobilize onto a 
gold electrode surface through strong thiol-gold bonds. The 3’ end of the aptamer 
is functionalized with the electroactive molecule methylene blue (MB). The 5’ 
extension of the aptamer is kept intact from the enzyme-selected structure and 
three thymine non-binding nucleotides are added to the 3’ end to match the 
number of nucleotides on the 5’ end, allowing close contact between the MB and 
the electrode surface upon target-induced folding of the aptamer structure. 
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4.3.9 Electrode surface modification and effects on signaling 
 
Initially, we prepared the Ade-29-MB-based sensor using a previously reported 
method of surface modification with 6-mercapto-1-hexanol (MCH).94 MCH can 
remove non-specifically bound aptamer molecules from the gold surface and lead 
to a more organized monolayer and large population of “active-sensing” 
aptamers.95 The results were promising, with addition of adenosine leading to a 
large positive change in the current while addition of ADP and ATP did not change 
the current (Fig. 36). The sensor was slightly cross-reactive for ATP and ADP when 
performing detection in a buffer with 1 mM magnesium, which could be a result of 
the higher local magnesium concentration at the electrode surface and nonspecific 
folding of the aptamer even in the absence of the target.195 Therefore, we 
performed the rest of the testing in buffer without any magnesium which resulted 
in minimal cross-reactivity (Fig. 36). Sodium was added to aid in conductivity of the 
solution but it did not cause any effect on target binding (fig. 37). 
 
 
 
Figure 36. Platform for electrochemical sensing of adenosine using the adenosine 
specific Ade-29-MB aptamer. 
(a) In the absence of adenosine, the redox probe is far from the electrode surface, 
thus only a small current is produced through the flexibility of the probe which can 
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strike the surface at a slow rate. A target-induced change in the aptamer 
conformation results in folding of the aptamer, bringing the redox tag into proximity 
of the electrode surface and increasing the rate of electron transport and thus the 
measured current. There is an equilibrium between the non-binding state (ss-DNA) 
and the binding competent state which directly affects the binding affinity and the 
background current. (right) Output current from addition of different targets ([target] 
= 250 µM) as detected by Ade-29-MB. Only specific binding of adenosine results 
in an increase in the measured current. 
 
 
 
Figure 37. Magnesium and sodium effect on electrochemical detection. 
Aptamer specificity is reduced in electrochemical measurements in the presence 
of 1 mM magnesium. This is likely a result of increased local concentrations of 
magnesium at the electrode surface, which is negatively charged. The specificity 
can be regained by lowering the magnesium concentration in the buffer. Sodium 
did not affect the electrochemical signaling. 
 
Aiming to increase the signal gain of the sensor, we tested a combination of MCH 
and dithiothreitol (DTT) as backfillers, with DTT being able to fill most pinholes in 
the monolayer structure reducing noise and displacing non-specifically bound 
nucleotides as well as increasing inter-aptamer distances which could aid in target 
binding.98,216 Interestingly, we observed higher signal gain with a combination of 
MCH/DTT as compared to MCH or DTT alone (Fig. 38a). The higher signal gain 
resulted in better performance at low concentrations of adenosine, enhancing the 
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sensor sensitivity (fig. 38b). This is a result from lower background current as well 
as higher signal gain upon target binding which could be explained by better 
monolayer stability, reduced non-specific interactions between the aptamer bases 
and the electrode surface and better aptamer spacing on the gold surface.216 
Dithiothreitol (DTT) alone significantly increased the electron transfer rate similarly 
as to what was previously observed by using short alkyl-chain backfillers, but 
resulted in lower signal gains because of increased background current.97 The 
aptamer surface coverage on the gold electrode was similar for MCH, MCH/DTT 
and DTT, therefore it is unlikely that the signal enhancement was a result of more 
probes being present on the surface (Fig. 38c). Signal response and equilibration 
times were also improved with the mixed monolayer of MCH/DTT as compared to 
MCH (data not shown). The amplitude was also optimized, with 25 mV resulting in 
the best signal gain (fig. 38d). It is possible that the mixed monolayer could be 
generally applied to other aptamer sensors but further investigation is required to 
understand whether this effect is specific for the Ade-29-MB aptamer. 
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Figure 38. MCH and DTT effect on electrochemical sensor and optimization. 
Various backfiller molecules were utilized to stabilize the gold-aptamer monolayer. 
(a) A combination of MCH/DTT resulted in the highest signal gain sensors at all 
frequencies tested. This is likely a result of better inter-aptamer spacing and lower 
non-specific adsorption of molecules to the electrode surface. (b) The MCH/DTT 
combination has better analytical performance, specially at lower adenosine 
concentrations, with higher apparent binding affinity. (c) The surface coverage was 
unchanged regardless of the backfilling molecule. This suggest that any 
improvement in the signaling is not a result of number of DNA aptamers 
immobilized on the surface of the electrode. (d) The amplitude of MCH/DTT 
modified electrodes was optimal at 25 mV at all frequencies. 
 
4.3.10 Detection of adenosine in undiluted and unprocessed serum 
Calibration curves were collected by titrating targets into a 4-mL electrochemical 
cell (Fig. 39). A hill binding model was utilized for fitting the titration curves which 
resulted in an apparent binding affinity slightly lower than ITC likely because 
detection was performed in buffer without magnesium and the surface 
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immobilization often affects affinity. We observed a weak cooperativity from the 
fitting which corresponds well with other reported methods and our own ITC data. 
Signal saturation was reached around 1 mM with a signal maximum of 120% and 
with a linear range from 1-50 uM in buffer (Fig. 39a and b). The frequency was re- 
optimized for detection in whole serum to account for the change in viscosity of the 
solution which has previously been reported to slow the rate of electron trasnfer.192 
However, the results indicated that the optimal frequency was also 100 Hz. in 
whole serum (Fig. 39a). We could perform detection immediately after target 
addition and observed complete signal saturation after 30 seconds (Fig. 39c). 
Signal saturation was also around 1 mM in undiluted serum with a linear range 
from 1-100 uM (fig. 39c). Detection in serum resulted in reduced signal gain 
because of the endogenous concentration of magnesium and other ions. The 
magnesium concentration in serum is reported to be between 1 - 4 mM. This 
produces a higher background current presumably because of stabilization of the 
binding competent state in the absence of target accounting for about 20% signal 
loss (Fig. 40c). The rest of the difference is attributed to the viscosity of the serum 
and possible degradation of the reference electrode. Measurements in undiluted 
serum also present higher cross-reactivity because of the endogenous magnesium 
concentration (Fig. 40c). Simply adding EDTA (2.5 mM) to the detection solution 
to quench the endogenous magnesium is sufficient to regain the desired specificity 
(Fig. 40c). Under such conditions, adenosine detection is specific compared to 
ATP, ADP, AMP and GTP (fig. 41) even under significant differences in the 
concentration of the targets. 
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Figure 39. Electrochemical detection of adenosine in buffer and serum. 
(a) Calibration curve of adenosine in buffer with linear range (inset) between 1 – 
50 µM and a maximum signal gain of 120% (b) Raw current response from SWV 
experiment with increasing concentrations of adenosine. (c) Calibration curve for 
adenosine in undiluted serum spiked with increasing concentrations of adenosine 
reported as signal gain percentage with linear range between 1 – 50 µM(inset). (d) 
Comparison of normalized signal gain and specificity of adenosine over ATP and 
ADP in buffer and undiluted serum with 2.5 mM EDTA and 500 µM of each target. 
 
 
 
Figure 40. Serum optimization and cross-reactivity in undiluted serum. 
(a) Frequency optimization in whole serum exhibited an optimal of 100 Hz. which 
was utilized for all other experiments. (b) Signal gain over time in undiluted serum. 
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Adenosine detection can be performed immediately after target addition and with 
signal saturation within 30 seconds. (c) Cross-reactivity in serum presumably 
because of endogenous magnesium and other divalent ions. EDTA can be added 
to quench the free divalent ions in undiluted serum to regain the desired specificity. 
[Target] = 500 µM. 
 
 
 
Figure 41. Adenosine specific detection and cross-reactivity with ATP, ADP, AMP 
and GTP. 
The Ade-29-MB aptamer is highly specific for adenosine when compared to ATP, 
ADP, AMP and GTP. AMP has even lower interaction with the aptamer, likely due 
to strong repulsion between the alpha phosphate and the thymine at position 23. 
[Target] = 250 uM 
 
4.4   Conclusion 
 
Initially, we hypothesized that nucleotide substitutions near the binding site would 
modulate the aptamer specificity. Indeed, our new adenosine aptamer varies at a 
single nucleotide and displays over 10-fold higher affinity for adenosine compared 
to ATP. The sensor was utilized to measure adenosine in undiluted serum with 
nearly no response for ATP or ADP, demonstrating its potential use in medical 
settings with similar performance as compared to buffer. The Ade-29 aptamer 
exhibits increased specificity for adenosine while retaining the same stem-loop 
structure of the original aptamer. The ability to use the same aptamer stem-loop 
structure is valuable as many methods have been developed for this structure and 
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sufficient characterization has been published, opening the door for further 
increasing the sensitivity of the sensor with adaptation to different signaling 
mechanisms. For example, graphene-based methods can be readily used with our 
structure-switching aptamer. The potential applications for this sensor will be in 
directly measuring adenosine in blood/serum samples to diagnose potential 
diseases, as a research lab tool in studies of the role of adenosine in various 
diseases, and potential identification of new therapies where adenosine 
concentration is important. We also envision the use of this sensor to indirectly 
measure the activity of adenosine regulating enzymes such as adenosine 
deaminase (ADA), adenosine kinase (ADK) and S-adenosylhomocysteine 
hydrolase (SAHH) and profiling of potential inhibitors of these enzymes. All of this 
is a direct result of the ability of the aptamer to measure adenosine in the presence 
of ATP, ADP, and AMP, which are the major sources of adenosine. Limitations of 
the newly identified Ade-29 aptamer include the increased cross-reactivity in the 
presence of high concentrations of magnesium which likely prohibits its use in 
continuous detection for neuromodulator release measurements in its current state 
and its limited sensitivity. We believe these obstacles can be overcome with further 
engineering of the aptamer sequence, improvements to the electrochemical 
detection method and adaption to different read-out methodologies. 
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CHAPTER 5 
 
Nuclease-guided truncation of aptamers for optimal structure-switching 
functionality and application in electrochemical sensors 
Aptamers which do not undergo conformational changes upon target-binding 
cannot be easily incorporated into signal transduction mechanisms. Conventional 
methods to instill structure-switching functionality -to otherwise conformationally 
static aptamers- often involve meticulous and labor-intensive testing of various 
‘pilot’ sequences. To enhance, facilitate, expedite and lower the cost of finding 
optimal structure-switching aptamers, we employ a T5-exonuclease guided 
method that truncates conformationally static aptamers, yielding aptamer 
sequences with large difference in the target-bound and un-bound states, with 
target-induced change in the conformation. The method was demonstrated to 
generate aptamer sequences with target-induced structure-switching functionality 
for the schedule I drug methylenedioxypyrovalerone (MDPV) and medical 
biomarkers deoxycorticosterone 21-glucoside (DOG) and adenosine triphosphate 
(ATP). Incredibly, identification of an optimal truncated aptamer can be achieved 
in a single experiment, from a single aptamer parent sequence. Additionally, DNA 
without expensive purification can be utilized, providing a low-cost alternative to 
generate optimal structure-switching aptamers. The method provides a key tool in 
development of E-AB sensors by lowering the cost, development time and 
complexity of aptamer engineering for electrochemical transduction. 
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5.1 Introduction 
 
Electrochemical aptamer-based (E-AB) sensors are becoming increasingly 
popular for detection of various targets in complex sample matrices (e.g., human 
serum and adulterated drugs).10,90 Functionality in complex samples is provided by 
the incredible specificity of aptamers, which can recognize even small changes in 
the structure of a molecule, and the high selectivity of electrochemistry because of 
the paucity of electroactive species in most samples.194 The success of these 
sensors largely lies in the ability to couple the binding reaction -between analyte 
and aptamer- into a measurable electronic signal (i.e., current). Electrochemical 
signaling occurs via a target-induced conformational changes in the aptamer 
structure, which modulates the rate of electron transfer between an electroactive 
molecule (covalently modified onto the aptamer) and the immobilizing electrode 
surface (Scheme 1).215 Transfer of electrons (i.e., signal-output) is determined by 
the distance of the redox-tag from the electrode surface and flexibility of the 
aptamer structure -both phenomena are directly affected by the aptamer 
secondary structure (i.e., conformation).92 
Aptamer selection strategies often isolate aptamers with relatively fixed (i.e., semi- 
permanent) conformations, which do not undergo target-induced structure- 
switching. Therefore, development of E-AB sensors requires meticulous and 
expensive aptamer engineering to impart structure-switching functionality to 
otherwise highly stable (i.e., folded) aptamers.48,110 The most important factor for 
optimizing the signal gain in E-AB sensors is finding the correct aptamer sequence 
which can ‘switch’ between distinct conformations before and after target binding. 
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Scheme 1. Electrochemical aptamer-based (E-AB) sensor design. 
Aptamers can be chemically functionalized with an alkane-thiol group for 
immobilization onto electrode surfaces by strong thiol-gold bonds, preventing 
desorption of aptamers during fabrication and measurements. The short alkane- 
thiol functional group also provides stabilization during formation of the aptamer 
monolayer by hydrophobic interactions with a diluent alkane-thiol molecule 
(omitted for clarity, see chapter 4 for detailed structure). The opposite end of the 
aptamer is chemically modified with an electroactive molecule such as methylene 
blue. The aptamer functions as a target-sensitive ‘switch’, separating the 
electroactive molecule from the electrode surface and thus modulating the 
measured current as a function of analyte concentration. 
 
A method that can add structure-switching functionality to the currently available 
and extensive aptamer library is highly desirable. While aptamer isolation methods 
for direct selection of structure-switching aptamers have been previously reported 
with limited examples and applications, adapting the already available and 
extensive library would be immediately impactful.217 The main advantages of 
structure-switching aptamers are their remarkable specificity (since weak-binding 
and non-binding molecules don’t typically induce structure-switching) and their 
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compatibility with various transduction methods such as fluorescence, color- 
change and electrochemistry. Generally, conventionally isolated DNA aptamers 
form stable, folded structures with distinct geometries such as stem-loops and 
three-way junctions; in both cases, intramolecular helices stabilize formation of a 
binding pocket, such as a three-way junction (three stems stabilize a central 
binding pocket). Prediction of the lowest energy conformation is based on 
calculations of the energy stabilization of individual matched base-pairs and 
energy penalties of loops, non-binding nucleotides or mismatched base pairs.218 
Increasing the number of matched base-pairs shifts the conformational equilibrium 
towards a folded conformation while removal of stabilizing base-pairs or addition 
of mismatched base-pairs would destabilize the structure until an unfolded 
structure is favored (Scheme 2). 
 
 
 
Scheme 2. Stem-length effect on aptamer conformation. 
Aptamer structures with long stems are highly stable and almost completely folded 
into organized and rigid double-stranded structures with little conformation 
difference upon target-binding. As the number of stabilizing base-pairs in the stem 
is reduced, the aptamer is destabilized and unfolds into a disorganized and flexible 
structure of single-stranded DNA. A minimum number of base-pairs is required for 
target-binding, with conventional methods requiring complex and costly aptamer 
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re-engineering to discover the correct structure-switching sequence and structure. 
 
Several strategies have been demonstrated to instill structure-switching 
functionality to aptamers including: (a) destabilization by trial-and-error truncation 
or mutation of the native aptamer structure such as removing base pairs or adding 
mismatched nucleotides, (b) separation of the folded binding pocket by addition of 
a polymer linker or long sequences of non-binding nucleotides and (c) addition of 
a competing oligonucleotide strand that will hybridize with the aptamer, block the 
binding site, and lock the aptamer in a distinct open conformation. The competing 
oligo strand can be displaced by target-specific binding (Scheme 3). These 
processes require careful and meticulous design, re-engineering and expensive 
testing of various aptamer sequences to find the sensitive equilibrium between the 
non-binding state and the bound-state.48,101 Additionally, such aptamer 
engineering can often lead to degradation of the analytical characteristics of the 
aptamer. For example, Li et al. developed and utilized a competitive DNA strand 
strategy (scheme 3c) to develop a structure-switching aptamer for ATP detection. 
The affinity of the partially blocked aptamer is heavily affected, with a reported 
reduction in the equilibrium dissociation constant by up to 60-fold, an effect of 
competition with the oligo strand.83 Indeed, the length of the competing strand must 
be carefully designed otherwise the target will not be able to bind to the aptamer. 
This method is also not conveniently adaptable to E-AB sensors since it requires 
addition of exogenous reagents and long incubation times to hybridize the 
immobilized probe to the competing oligonucleotide strand. Elsewhere, 
destabilization and addition of linking groups to separate binding sites have also 
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been explored. White et al. engineered various derivatives of the original ATP 
aptamer to compare the effects of destabilization and pseudo-sandwich (bridged) 
designs (scheme 3, a and b).48 They concluded that destabilization provided the 
highest signal gain sensors, with ease of adaptability to E-AB sensing since the 
aptamer does not require any exogenous reagents for detection. White et al. also 
reported destabilization by truncation of the cocaine aptamer for efficient target- 
induced sensing and similar results for the thrombin aptamer.87 
 
 
 
Scheme 3. Methods to add structure-switching function to aptamers. 
Most reported aptamers display stable, mostly folded structures with long regions 
of rigid intramolecular helices (i.e., dsDNA). These aptamers adopt a semi- 
permanent and optimal conformation to minimize energy barriers to bind the 
analyte. Several strategies have been developed to change the resting 
conformation including: (a) removing stabilizing base pairs from stem regions, 
causing unfolding of the aptamer structure that can only be repaired by target- 
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aptamer binding. (b) Addition of long linker bridges that divide the binding motif 
into distinct sites that can only be reunited upon target addition. (c) Addition of a 
competing strand that blocks the binding site but can be displaced by target- 
induced aptamer folding.48 
 
Destabilization by truncation of various aptamers has resulted in aptamers that 
exhibit structure-switching functionality and have been successfully incorporated 
to E-AB sensors. Unfortunately, design of such structures requires prior knowledge 
of the secondary structure of the aptamer and meticulous and expensive testing of 
multiple ‘pilot’ sequences.48,101 We describe a nuclease-based method that 
truncates the aptamer structure but is inhibited close to the binding site by 
formation of target-aptamer complexes, yielding aptamer sequences with 
structure-switching functionality without requiring complex, lengthy and expensive 
aptamer engineering. 
Several purified enzymes exhibit exquisite specificity for hydrolysis of distinct DNA 
conformations (e.g., single-stranded vs. double-stranded DNA). For example, Lou 
et al. employed exonuclease I, which hydrolyzes single-stranded DNA but not 
double-stranded DNA, to create sensors for various aptamer targets including the 
small molecule cocaine. The employed aptamers exhibited disorganized and 
flexible structures prior to target binding that were susceptible to hydrolysis by the 
exonuclease I; Binding of target resulted in folding of the aptamer to a rigid double- 
stranded structure that was not susceptible to hydrolysis by exonuclease I. The 
undigested aptamer product could be quantified by addition of a DNA-binding 
fluorescent dye, with increasing fluorescence being proportional to target 
concentration in the sample.157 Unfortunately, the method requires prior 
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knowledge of the folding dynamics of the aptamers and predicted structure 
changes upon target binding. Wang et al. recently described an exonuclease III- 
based system to instill structure-switching functionality to small molecule 
aptamers. Exonuclease III can digest double-stranded DNA specifically from blunt 
or recessed 3’ ends in the 3’ to 5’ direction; Surprisingly, aptamer-target complexes 
inhibit digestion by exonuclease III 4-nt (nt: nucleotides) away from the presumed 
binding site.110 Enzyme truncation of several nucleotides yielded aptamers 
sequences with shorter stabilizing stems that were proven to undergo structure- 
switching functionality. Similarly, we developed a method utilizing T5 exonuclease 
as a catalyzing molecule to probe DNA aptamer conformation in the 5’ to 3’ 
direction to identify optimal structure-switching aptamer sequences. T5- 
exonuclease has been previously shown to catalyze the hydrolysis of linear single- 
stranded DNA, double-stranded DNA, 5’ overhangs and 3’ overhangs in the 5’ to 
3’ direction.111,112,114,219–221 Thus, T5 exonuclease is an excellent complement to 
exonuclease III, which acts in the 3’ to 5’ direction with similar enzymatic activity. I 
hypothesized that T5 exonuclease would be inhibited close to the presumed 
binding site by formation of aptamer-target complexes as its observed in the 
exonuclease III system. In the absence of target, the enzyme will freely track along 
the DNA sequence from the 5’- end and catalyze the hydrolysis of the aptamer 
molecule with activity for both the single- and double-stranded DNA aptamer 
conformations. In contrast, formation of an aptamer-target complex will inhibit the 
enzyme progress close to the binding site, providing truncation of the parent 
aptamer and yielding a minimal-length aptamer sequence which is preferentially 
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unfolded in the absence of target, but can readily form a stable, enzyme-inhibiting 
folded structure upon target-binding. Herein, T5 is utilized to smartly truncate 
aptamers to yield structure-switching aptamers for small molecules including the 
synthetic cathinone MDPV and medical biomarkers DOG and ATP. 
5.2 Methods 
 
T5 Exonuclease was purchased from New England Biolabs (10 U/µL) and stored 
in 5 µL aliquots at -30°C. Methylenedioxy pyrovalerone (MDPV) was purchased 
from Cayman Chemicals. Stock solutions were prepared in 100% methanol at 
concentrations of 32 mM and stored at -30°C. ATP was prepared in a buffered 
solution at a concentration of 37 mM, as measured using absorbance and an 
extinction coefficient of 15.4 mM-1. DOG and DIS were prepared in 100% DMSO 
and stored at -30°C. Oligonucleotide sequences were purchased form IDT-DNA 
without purification with only standard desalting. DNA stock solutions were 
prepared by dissolving in nuclease-free water with average concentrations of 100 
µM. DNA concentration measurements were performed in a Nanodrop instrument 
with the specific extinction coefficient as provided by the company. Stocks were 
stored at -30°C in 5 µL aliquots. The following sequences were utilized: 
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Table 4. DNA sequences, substitution and mutations. 
 
 
Note: Red outline indicates the conserved aptamer binding sequence for DOG. 
 
5.2.1 T5 enzyme reaction 
 
DNA stocks were first diluted to 1 µM and placed on a hot plate at 95°C for 10 
minutes to completely denature the aptamer structure. The DNA solution was then 
placed in ice to obtain the lowest energy, folded sequence. The buffer employed 
for the enzymatic reaction was NEB-4 as suggested by the company for optimal 
catalysis (1x NEB-4: 20 mM tris-acetate, 50 mM potassium-acetate, 10 mM 
magnesium acetate, 1 mM dithiothreitol (DTT) at pH 7.9). The aptamer mixture 
was then incubated with the appropriate target for 30 minutes at 23°C. MDPV stock 
solution was prepared by vacuum centrifuging to evaporate the methanol solution 
and isolate the solid MDPV. Water was added to the MDPV solid to appropriately 
match the desired concentration. T5 enzyme was diluted on ice to a final 
concentration of 1 U/µL and added to a 90% buffer mixture with DNA:enzyme ratio 
of 1 µM:0.1U/µL. The mixture was manually mixed and centrifuged prior to 
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incubation at 23°C. The reaction was stopped at various times by dilution with a 
stop mix gel loading buffer consisting of 3.5 M urea and 50% formamide. (1 part 
DNA: 4 parts loading buffer) 
5.2.2 Gel Electrophoresis 
 
Denaturing gel electrophoresis (8M urea) was performed to separate and analyze 
the enzymatic reaction products. Polyacrylamide gels were prepared by mixing 5 
mL DI, 10 mL 5X TBE and 20 mL (40% acrylamide) with 21 g of Urea. The solution 
was mixed on a hot plate at 30°C until the urea dissolved. Freshly prepared 10% 
APS and TEMED were then added and polymerization occurred at room 
temperature for 2 hours. The gels were pre-run at 450V and the final sequence 
analysis was a two-step method, 100V for 30 minutes and 400V for 3 hours. 
Samples were loaded as prepared during the enzymatic reaction, 4 µL per well. 
DNA markers were prepared in-house by mixing sequences with increasing 
lengths and matching the concentrations to obtain a uniform band intensity. 
Ladders were appropriately loaded to calculate the length of resulting products. 
Band intensity was compared to a control band without any enzyme to estimate 
the concentration of products. 
5.3 Results and discussion 
 
5.3.1 MDPV aptamer truncation 
 
T5 exonuclease is utilized to probe the aptamer structure in the 5’ to 3’ direction 
because of its ability to catalyze the hydrolysis of linear single-stranded and 
double-stranded DNA conformations.112 I hypothesized that T5 exonuclease would 
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be inhibited close to the presumed binding site by formation of aptamer-target 
complexes. We utilized a novel methylenedioxy pyrovalerone (MDPV)-binding 
aptamer that was recently selected in our lab as a test bed. The enzymatic reaction 
was monitored by denaturing gel electrophoresis to identify the enzyme products 
and estimate their length by comparison to a DNA-marker. In the absence of 
MDPV, T5 can hydrolyze the aptamer structure yielding short oligonucleotide 
enzymatic product fragments of 21- and 22-nt (where -nt stands for nucleotides). 
Aptamer binding to the MDPV target severely inhibited T5 close to the presumed 
binding site, with a main enzyme reaction product of 41-nt, which is 5-nt less than 
the starting parent aptamer of 46-nt (Fig. 42a). Prior to T5-guided truncation, the 
aptamer stabilizing stem consists of 8-base pairs, most of which are presumably 
not involved in binding to the target but still stabilize the folded conformation and 
possibly prevent structure-switching upon target-binding (Fig. 42b). After T5- 
guided truncation, the aptamer stem is reduced to 3-base pairs, which appears to 
be the minimum stem-length required for binding to the MDPV target. It is well 
established that reducing the stem length leads to increased possibility of 
structure-switching functionality, thus it is likely that the T5 truncation product can 
undergo structure-switching upon target-binding (fig. 42b, bottom).48,62,102 For 
quick comparison of the enzymatic reaction products, the aptamer structure is 
color-coded. In the absence of target, the enzyme reaction product is represented 
by a red outline. In the presence of target, the enzyme reaction product is 
represented as a combination of the red and a blue outline. 
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Figure 42. T5-guided truncation of an MDPV-binding aptamer yielding a structure- 
switching sequence. 
(a) T5 exonuclease was utilized to digest the MDPV-aptamer. In the absence of 
target, T5 catalyzes the hydrolysis of the aptamer structure, yielding short 
fragments of 22- and 21-nt. Formation of an MDPV-aptamer complex inhibits T5 
activity 3-nt away from the presumed binding site, producing a distinct product of 
41-nt. A control band is shown without addition of enzyme and a DNA marker is 
utilized to approximate the length of the enzymatic products. (b) The originally 
selected aptamer displays a long stabilizing stem which prevents target-induced 
structure-switching (top). The T5-truncated aptamer has a much shorter stabilizing 
stem of 3 base-pairs which possibly exhibits target-induced structure-switching 
(bottom). The colored lines indicate the enzyme reaction products in the absence 
(red; 19- and 20-nt) and presence (blue + red; 41-nt) of MDPV. [T5] = 0.1 U/µL, 
[DNA] = 1 µM, [MDPV] = 320 µM at 23°C for 120 minutes. 
 
The T5 reaction was stopped at different times by mixing with formamide and 
EDTA to examine the reaction products over time. A control sample of constant 
concentration was utilized to estimate the concentration of the enzymatic products. 
In the absence of a binding target, several enzymatic products are observed over 
a time window of five hours. In the absence of target, T5 reaction for 15 minutes 
yields a singular 41-nt product with an estimated concentration of 800 nM (80% of 
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the starting material). Interestingly, the 41-nt product is still present even after two 
hours of reaction, suggesting the enzyme unbinds with the DNA at this point 
possibly because of a change in the conformation of the structure and must re- 
bind to digest the new aptamer conformation. After 120 min, the 41-nt product is 
only faintly present with a concentration of 100 nM and it is eventually completely 
digested after 5 hours (fig. 43). In contrast, two reaction products are observed 
after 15 minutes of incubation with T5 in the presence of MDPV with lengths of 42- 
nt and 41-nt and concentrations of 450 nM each (fig. 43, plotted as a combined 
concentration). After 120 minutes, most of the 42-nt product is enzymatically 
converted to the 41-nt product and the estimated concentration of the 41-nt product 
at this point was 600 nM (fig. 43). Even after 5 hours of T5 digestion, the MDPV- 
aptamer mixture exhibits a 41-nt product with an estimated concentration of 550 
nM (fig. 43). Thus, we proved that formation of MVPD-aptamer complex inhibits 
T5 activity and the inhibition product of 41-nt possibly has different conformations 
in the absence and presence of MDPV. This method can possibly identify a 
structure-switching aptamer in a single experiment, without requirements for 
complex aptamer engineering or labor-intensive testing of multiple sequences. 
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Figure 43. Time course of T5 reaction and characterization of enzyme reaction 
products visualized utilizing gel electrophoresis. 
T5-exonuclease can quickly digest nucleotides that are not involved in binding to 
the target and within two hours most of the parent aptamer is hydrolyzed in the 
absence of target. However, in the presence of MDPV, formation of the aptamer- 
target complex inhibits T5 digestion and results in a truncated product of 41-nt. 
This suggests that formation of a folded aptamer-target complex inhibits the 
enzyme progress. The intensity of the bands is converted to concentration by 
comparing to the control band which has a known concentration. [T5] = 0.1 U/µL, 
[DNA] = 1 µM, [MDPV] = 320 µM at 23°C. 
 
To confirm that T5 inhibition is a result of formation of MDPV-aptamer complexes 
and not a result of direct inhibition by MDPV, we designed truncated sequences of 
the MDPV aptamer which do not form the presumed hydrophobic binding site. The 
MDPV aptamer structure was manually truncated by deletion of 10- and 13-nt from 
the 3’ end yielding aptamer variants of 36-nt and 33-nt. The predicted folding was 
calculated with Mfold, a webserver to predict nucleic acid folding, to predict 
whether the three-way junction could be formed in the 33- and 36-nt aptamer 
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variants.222 These shorter fragments are not predicted to form a three-way junction 
because of the absence of complementary base-pairs, inhibiting target binding 
(see Mfold predicted structures in figure 44). T5 truncation of the non-binding 
sequences resulted in reaction products that were identical whether in the 
presence or absence of MDPV. For example, the 36-nt aptamer exhibited a main 
product of 28-nt and a concentration of 175 nM, about 17% of the starting material 
in the presence or absence of MDPV (fig. 44). The 33-nt aptamer after T5 
truncation yielding a major product of 25-nt regardless of the absence or presence 
of MDPV. T5 is only inhibited when the 46-nt binding aptamer is utilized, with a 
41-nt inhibition product of >500 nM (fig. 44). Thus, the inhibition of T5 is directly 
caused by binding of MDPV to the aptamer. To easily visualize and compare the 
products of the enzymatic reaction to the starting structure, a color-guide outline is 
utilized. For example, the starting aptamer of 46-nt is a combination of the gray, 
red and blue outlines. T5-exonuclease removes 5-nt from the starting structure 
yielding a main product of 41-nt in the presence of MDPV, represented by the blue 
and red outlines combined. In the absence of target, the main products are shown 
in a red outline, with lengths of 22- and 21-nt (Fig. 44, bottom). From this scheme, 
it can be observed that only the 46-nt aptamer bound to MDPV inhibits T5 activity 
and yields a different product in the presence of MDPV. 
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Figure 44. T5 inhibition is caused by formation of a MDPV-aptamer complex and 
not by MDPV itself. 
(a) Gel electrophoresis enzyme products of different aptamer sequences in the 
presence and absence of target. The truncated non-binding sequences (33-nt and 
36-nt) do not exhibit any MDPV-induced inhibition. However, the 46-nt binding 
aptamer exhibits significant MDPV-induced inhibition of T5 digestion with a 
singular product of 41-nt and concentration of >500 nM (represented by the blue 
and red outline combined). In the absence of target, short products of 22- and 21- 
nt are observed (represented by the red outline). [T5] = 0.1 U/µL, [DNA] = 1 µM, 
[MDPV] = 320 µM at 23°C for 120 minutes. 
 
5.3.2 Comparison with T7-exonuclease 
 
Enzymatic inhibition by formation of aptamer-target complexes has been 
demonstrated with exonuclease III (3’-5’ direction) previously and with T5- 
exonuclease (5’-3’ direction) in this work. To study whether this is phenomenon is 
generalizable, I employed T7-exonuclease to determine if aptamer-target 
complexes could also inhibit T7 activity. T7-exonucelase has been widely reported 
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to have incredible specificity for double-stranded DNA, with activity from blunt or 
recessed 5’ ends.223–225 Indeed, a singular mismatched base-pair can result in 
inhibition of T7 enzymatic activity.226 I hypothesized that T7 would be able to 
hydrolyze aptamer structures with stable stems but be inhibited close to the binding 
site as observed with T5 and exonuclease III. We tested the same 46-nt MDPV- 
binding aptamer to compare T5 and T7 for aptamer truncation. T5 can truncate the 
aptamer to yield a product of 41-nt in the presence of MDPV but T7 is not able to 
digest the aptamer structure in the absence or presence of target (fig. 45). Even 
after 4 hours of T7 reaction, the same parent aptamer is observed suggesting the 
enzyme is not able to catalyze hydrolysis of this aptamer structure even though it 
exhibits a favorable double-stranded substrate. It is notable that T7 exonuclease 
does not have activity for single-stranded DNA. In contrast, both T5-exonucelase 
and exonuclease III have both single- and double-stranded activity. At least in this 
case and under the current experimental conditions, it appears that only T5 
exonuclease is capable of aptamer truncation. 
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Figure 45. Comparison of aptamer truncation with T5- and T7-exonuclease. 
Two enzyme-based methods were tested with the MDPV binding aptamer. As 
expected, T5 could differentiate between aptamer-bound and aptamer-free 
structures. However, T7 did not digest either structure even though it has been 
previously reported to be highly specific for double-stranded DNA. [T5] = 0.1 U/µL, 
[T7] = 0.2 U/µL, [DNA] = 1 µM, [MDPV] = 320 µM at 23°C. 
 
5.3.3 ATP-binding aptamer truncation 
 
I studied T5 truncation of the ATP-binding aptamer to prove T5 could truncate 
aptamer structures other than three-way junctions. The ATP aptamer has a stem- 
loop structure with a 4-base pair stabilizing stem and a reportedly folded 
conformation even in the absence of target, with limited structural change upon 
target binding.208,210,227,228 Indeed, White et al. performed urea denaturation 
studies and found that >99.6% of the ATP-aptamer molecules are folded in the 
absence of target.48 In contrast, reducing the stem length by 2 base-pairs results 
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in the unfolded aptamer confirmation dominating the conformational equilibrium. I 
hypothesized that T5 would be inhibited as it approached the presumed binding 
site by formation of the ATP-aptamer complex. I modified the previously reported 
ATP-binding aptamer by adding 3’ and 5’ overhangs of 5-nt each but otherwise 
conserved the same sequence as the original ATP aptamer of Huizenga et al.47 
The overhangs have been reported to provide a better binding substrate for T5.113 
Thus, the utilized ATP-binding aptamer has a 37-nt long sequence (fig. 46, 37-nt). 
As predicted, T5 can truncate 6-nt from the starting aptamer sequence of 37-nt, 
yielding a product of 31-nt corresponding to a structure with a 3 base-pair stem 
(fig. 46). The concentration of the 31-nt product was plotted over the time course 
of the reaction and exhibited a consistent value of >900 nM even after 5 hours 
(90% starting concentration). I previously utilized a similar construct with stem 
length of 3 base-pairs for detection of adenosine and proved that it underwent 
significant target-induced conformational changes (see chapter 4). Thus, T5 
truncation of the ATP aptamer can yield an aptamer sequence that possibly 
undergoes structure-switching. In the absence of target, two products are 
observed over the reaction time course of five hours with lengths of 31-nt and 30- 
nt and corresponding stems of 3 and 2 base-pairs, respectively (fig. 46). After 5 
hours only the 30-nt product remains at a concentration of nearly 300 nM. The 30- 
nt structure with the 2 base-pair stem was previously proven to be unfolded in the 
conformational equilibrium48, thus it appears from these results that under the 
current conditions, digestion of single-stranded DNA by T5 is slow. After 8 hours, 
the 30-nt band is consumed in the absence of target but still retained in the 
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presence of target (data not shown). 
 
 
 
 
Figure 46. Time course of T5 reaction with ATP-binding aptamer. 
Digestion of the aptamer proceeds quickly at first as the 5’ overhang is a good 
enzyme substrate, with most of the parent aptamer being processed within 15 min. 
In the absence of target, the enzyme can digest most of the structure, yielding a 
minor product of 30-nt and concentration of 300 nM. However, in the presence of 
target, T5 truncation yields two products of 31- and 30-nt. The major product is 31- 
nt with a corresponding stem of 3 base-pairs and a consistent concentration of 
>900 nM over the five-hour reaction window. (right) The band intensity is converted 
to concentration by utilizing a control band of known concentration without enzyme 
addition. [T5] = 0.1 U/µL, [DNA] = 1 µM, [ATP] = 500 µM at 23°C. 
 
An ATP non-binding sequence was tested to confirm that ATP did not inhibit T5 
directly. The non-binding sequence was designed by removal of 8-nt from the 3’ 
end of the aptamer sequence and 2-nt from the 5’ end and termed ATP.25. The 
25-nt sequence is not able to form the binding pocket and it also lacks an essential 
binding nucleotide as has been previously described.47 T5 truncation of the ATP.25 
yielded the same 20-nt product regardless of the presence or absence of ATP, 
proving that ATP does not actively inhibit the enzyme (fig. 47). In contrast, the 37- 
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nt ATP binding aptamer inhibited T5 by formation of the ATP-aptamer complex, 
yielding the described 31-nt product. A secondary product is observed if the 
reaction is left to proceed for longer time, with truncation of 7-nt yielding a product 
of 30-nt which correspondingly has a stem of 2 base-pairs. This 30-nt structure 
has also been previously reported to retain binding affinity for ATP, thus it appears 
T5 can recognize two separate aptamer products that can undergo structure- 
switching upon target binding.48 The same color-guide is employed to describe the 
different reaction products in the presence and absence of ATP as described in 
the last section. The T5-guided strategy enables simpler and faster identification 
of the structure-switching sequences for stem-loop structures. 
 
 
Figure 47. T5 inhibition is caused by formation of aptamer-ATP complexes and 
not by ATP directly. 
A manually truncated non-binding sequence was tested (25-nt) and yielded the 
same product of 20-nt regardless of ATP presence or absence. This proves that 
ATP does not directly inhibit T5 activity. In contrast, the 37-nt ATP-binding 
sequence underwent T5-guided truncation yielding products of 31- and 30-nt. Both 
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of these products have been previously shown to retain affinity for ATP. The 
column plot represents the band intensity as a measurement of concentration. [T5] 
= 0.1 U/µL, [DNA] = 1 µM, [ATP] = 500 µM at 23°C for 340 minutes. 
 
5.3.4 DIS-binding aptamer truncation 
 
To further test the generality of the method, I tested aptamers which specifically 
bind the small molecule steroids deoxycorticosterone 21-glucoside (DOG) and 
dehydroisoandrosterone 3-sulfate (DIS). Stojanovic et al. previously isolated these 
three-way junction aptamers, which display long stabilizing stems and a binding 
pocket at the junction of the stems.229 The formation of the junction is required for 
binding as it creates a hydrophobic environment by display of aromatic groups of 
unstacked nucleotides at the junction, favoring binding of hydrophobic 
molecules.58 I utilized T5 to initially truncate the DIS-binding aptamer to yield the 
minimum number of base-pairs required for binding of DIS while maximizing the 
structure-switching ability of the aptamer. The DIS-binding aptamer structure was 
almost fully digested in the absence of binding target with nearly zero bands 
present in the lane of this sample (fig. 48, DIS). Incubation with DIS resulted in 
nearly complete inhibition of the enzyme with concentrations of the product band 
being nearly uniform from the starting concentration, and the major product being 
the parent aptamer of 37-nt and a minor product of 36-nt (fig. 48, DIS). Truncation 
was not observed with the DIS-binding aptamer, suggesting that all the nucleotides 
in the stem are necessary for a high-affinity binding interaction with DIS. This is a 
possibility as formation of the binding pocket is required for binding of hydrophobic 
molecules.58,229 Indeed, a recently reported and improved DIS-binding aptamer by 
Stojanovic et al. has equally long stabilizing stems, suggesting the necessity for all 
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nucleotides for high-affinity binding.230 Thus, it is possible that truncation of these 
steroid-binding aptamers is not possible or necessary. 
 
 
 
Figure 48. T5-guided truncation of DIS-binding aptamer to identify structure- 
switching fragments. 
The DIS aptamer was digested in the absence of target as expected, with only a 
faint product band of 23-nt being observed in the gel image. Addition of DIS 
resulted in nearly complete inhibition of T5 yielding products that did not differ in 
length when compared to the control sample without enzyme. This might be 
possibly because all the nucleotides in the stem are required to stabilize a high- 
affinity interaction with DIS. [T5] = 0.1 U/µL, [DNA] = 1 µM, [Steroid] = 500 µM at 
23°C for 135 minutes. 
 
Direct inhibition of T5 by the steroid DIS was tested by incubating DIS with a control 
DNA sequence (an ATP-binding aptamer) that does not bind DIS. The T5 enzyme 
digested the control sequence at equal rates in the presence or absence of DIS, 
with multiple product bands present and concentration of the parent band below 
300 nM after 2 hours, demonstrating that DIS does not inhibit the enzyme directly 
(fig. 49a). The enzyme T7 exonuclease was also tested and did not digest the 
control sequence in any case (fig. 49a). It is mentioned and included because an 
increase in the intensity of the bands in the presence of DIS was present in all 
samples and was attributed to overlap between the fluorescence intensity of SYBR 
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gold (the fluorescence DNA stain) and DIS (fig. 49c).231 Thus, clearly the enzyme 
is not inhibited directly by DIS but rather it is possible that all the nucleotides in the 
stem are necessary for target binding under the employed conditions. 
 
 
Figure 49. Test of T5 inhibition by the steroid molecule DIS. 
(a) Gel electrophoresis of reaction products of an ATP-binding aptamer incubated 
with DI or DIS at varying times. T5 enzyme digestion of the control DNA was slow 
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and it did not vary in the presence or absence of DIS. T7 exonuclease also did not 
exhibit digestion of the control aptamer and a mixture of T5 and T7 exhibited similar 
response as T5 alone. (b) Time course plots of the band intensity (converted to 
concentration) exhibit decreasing band intensity over time, because of enzymatic 
hydrolysis and formation of shorter fragments. (c) A difference in the intensity was 
observed in the presence of DIS that was attributed to fluorescence overlap 
between DIS and the DNA staining dye, SYBR gold. The difference in intensity 
was present with both enzymes. This test proves that DIS does not inhibit T5 
directly. 
 
5.3.5 T5 activity on DOG-binding aptamer 
 
The DOG aptamer demonstrated the slowest rate of hydrolysis of all the aptamers 
tested (data not shown). I hypothesized that addition of a 5’- overhang would aid 
in the rate of digestion of the DOG aptamer, as the T5 enzyme can bind 5’ 
overhangs with higher affinity when compared to blunt double-stranded DNA.232 
We modified the DOG aptamer with 5’- overhangs of varying lengths, and a 5’ 
recessed end to study their effect on enzyme rate. Interestingly, the digestion of 
the 5’- overhang was very fast (<5 min.) but it appeared the enzyme would unbind 
from the aptamer structure upon cleaving the 5’ overhang, as a major product was 
observed at 41-nt regardless of the length of the 5’ overhang. A 5’ overhang of +7- 
nt resulted in a truncation of 8-nt, yielding a 41-nt product and truncation of the +3- 
nt overhang resulted in truncation of 4-nt, yielding the same 41-nt product (fig. 50, 
5 mins.). Digestion of the blunted or 5’ recessed aptamer structures was much 
slower, necessitating more than five hours to digest in the absence of target (fig. 
49, 300 mins). In the absence of target, a faint product is observed at 37-nt, 
corresponding to a short 3 base-pair stem which likely signals the stem position 
where structure-switching occurs. In the presence of DOG, various products are 
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observed although the majority only exhibit minor truncation. Like the DIS aptamer, 
the DOG aptamer likely requires all nucleotides in the stem for high-affinity 
interaction with the target. 
 
 
Figure 50. Digestion rate of T5 on 5’ overhangs and double-stranded DNA. 
Various aptamers were synthesized with increasingly longer 5’ overhangs to study 
the role of binding of the enzyme to 5’ overhangs and 5’ blunt ends. The 5’ 
overhangs exhibited fast digestion rates, with the extensions of all lengths being 
quickly cleaved at the double-stranded junction. Destabilization of the stem by 
reducing the number of base pairs resulted in identification of a truncated aptamer 
that displayed target-induced inhibition of the enzyme. This sequence presumably 
is the minimum number of base pairs that is required for dsDNA formation and 
inhibition of T5. [T5] = 0.1 U/µL, [DNA] = 1 µM, [Steroid] = 500 µM at 23°C. 
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Additionally, we tested a sequence where the DOG aptamer had a 5’ recessed 
end by 3-nt, thus only having a stem of 5 base-pairs. These 5’ recessed structures 
also reportedly promote binding of T5 compared to blunt DNA.232 Indeed, T5 can 
catalyze the hydrolysis of this structure in the absence of target and addition of 
target inhibits the digestion, yielding a truncated sequence with a 3-base pair stem 
(fig. 50, DOG.-3). Mfold simulations predict that the 5-base pair aptamer can form 
a stable, folded structure that presumably does not undergo significant structure- 
switching upon target-biding. However, the T5-selected 3 base-pair aptamer is 
predicted to form a highly flexible, unfolded sequence which can possibly undergo 
target-induced structure-switching.222 
A time-course of the reaction between T5 and the 5’ recessed DOG aptamer 
variant is shown in figure 51. In the absence of target, T5 can digest the aptamer 
structure until it reaches a product of 37-nt yielding a 3 base-pair stem. It is possible 
that at this point, the enzyme disengages from the aptamer structure because of a 
conformational change in the DNA. After 5 hours, the product at 37-nt is completely 
consumed by the enzyme (fig. 51). In the presence of DOG, T5 is inhibited close 
to the presumed binding site with a major product of 37-nt being observed even 
after 5 hours of reaction with a concentration of >600 nM remaining (fig. 51). The 
recessed aptamer can be utilized in combination with T5 to yield a structure- 
switching DOG aptamer. 
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Figure 51. Time course of T5 digestion of DOG.-3 aptamer structure and 
enzymatic products visualized using gel electrophoresis. 
The enzyme reaction was stopped by mixing of reaction buffer with stop-mix 
loading buffer containing high concentrations of EDTA, formamide and urea. The 
aptamer is digested at a faster rate in the absence of target, but the enzyme is 
significantly inhibited upon addition of DOG because of formation of DOG-aptamer 
complex. After 5 hours, the enzyme truncates 2-nt to yield an aptamer of 37-nt and 
a corresponding stem of 3 base-pairs (blue line) which appears to be the minimum 
number of base-pairs required for binding of target and addition of structure- 
switching functionality. [T5] = 0.1 U/µL, [DNA] = 1 µM, [Steroid] = 500 µM at 23°C. 
 
5.3.6 Engineering a DOG-binding aptamer for T5 truncation 
 
A DOG-binding aptamer was engineered by changing the stem sequence to 
closely match the initial 5 base pairs of the MDPV stem, which does not contain 
more than 2 consecutive C-G base pairs and is shown to be readily digested by 
T5 (red nucleotides in figure 52). The redesigned sequence can be fully digested 
in the absence of target at a much faster rate than the original DOG aptamer (Fig. 
52). Increased digestion was also observed in the presence of DOG, with a 
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truncated aptamer sequence being identified by the nuclease as a 3-base pair 
stem, matching the result using the shorter 5-base pair aptamer (Fig. 52). A smaller 
concentration of the 37-nt binding product is observed >300 nM. This might be a 
result of incomplete digestion of larger fragments as seen in the gel but could also 
be an effect of reduced affinity for DOG because of the nucleotide substitutions in 
the stem. It appears that truncation of steroid binding aptamers, which necessitate 
highly stable stems, might not be practical or necessary. 
 
 
Figure 52. T5-guided truncation of redesigned DOG aptamer sequence. 
(a) Time course of digestion of redesigned sequence with a 5’ overhang and 
several mutated nucleotides that match the MDPV stem. Digestion is faster as 
compared to the original sequence and in the absence of target completely 
consumes the parent aptamer within 130 minutes. In the presence of target, the 
main product has a 3 base-pair stem stabilized by target-binding which inhibits 
further enzymatic digestion. The band concentration is plotted as a function of time. 
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The blue line in the illustrations represents the product sequence that is identified 
in the presence of target and the red line in the absence of target. [T5] = 0.1 U/µL, 
[DNA] = 1 µM, [Steroid] = 500 µM at 23°C. 
 
5.4 Conclusion 
 
A T5-guided truncation method is demonstrated to easily and quickly truncate 
aptamers to yield aptamer sequences which possibly display structure-switching 
functionality and maintain high target affinity. We hypothesized that T5 
exonuclease would be inhibited by formation of aptamer-target complexes as is 
seen in small molecule footprinting studies utilizing exonuclease III and DNAse 
I.110,233 Indeed, formation of aptamer-target complexes inhibit the enzyme activity, 
with single or dual products only being observed in the presence of the target as 
compared to empty lanes in the absence of target. The method is used to identify 
aptamer fragments with structure-switching functionality for targets including 
MDPV, DOG and ATP. The enzyme T5 exonuclease demonstrates a unique ability 
to recognize the essential aptamer sequence for binding while removing any 
unessential nucleotides. The enzyme T7 exonuclease is unable to perform such 
function. This strategy will be a key tool -fast, simple, widely available, and low 
cost- in development of E-AB sensors which require aptamers with structure- 
switching functionality. 
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CHAPTER 6 
 
Summary and future directions 
 
6.1 Summary 
 
The dissertation describes methods to engineer aptamers to increase analytical 
performance, modulate specificity and add functionality with the goal of 
overcoming practical limitations of current aptamer-based sensors, especially for 
small-molecule detection in real-world sample matrices. In chapter 3, it was 
discovered that ATMND could bind to the cocaine aptamer, modulating its 
fluorescence when bound (quenched) or free (fluorescent) in solution. Addition of 
cocaine would displace the ATMND molecule from the aptamer binding pocket, 
resulting in an intense fluorescence signal that could be correlated to cocaine 
concentration. Additionally, a cocaine aptamer was engineered with 10-fold higher 
affinity for both molecules as compared to previously reported aptamers. The 
method was applied to detect cocaine in biological samples such as urine, saliva 
and serum. The sensitivity of the method was over 50-fold higher than other 
reported aptamer-based methods. The improvement in sensitivity was correlated 
to higher affinity for cocaine and sensitive fluorescence signaling from ATMND 
displacement. 
In chapter 4, an adenosine-specific aptamer was engineered by rational mutation 
of the aptamer sequence. A method to quickly screen the mutated sequences was 
also introduced, which aided in the identification of the adenosine-specific 
aptamer. The aptamer was truncated to introduce structure-switching functionality 
and adapted to an electrochemical transducer. The sensor could detect low 
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concentrations of adenosine in undiluted serum and exhibited minimal response 
to ATP, ADP and AMP. The sensitivity of the sensor was improved by 40-fold when 
compared to previously reported aptamer-sensors for undiluted serum 
measurements of adenosine. 
In chapter 5, a nuclease-guided method was developed to intelligently truncate 
aptamer sequences yielding aptamer fragments with structure-switching 
functionality. As opposed to trial-and-error methods, no prior knowledge of the 
binding site is required to yield truncated aptamers. Aptamers with structure- 
switching functionality can be used directly in a variety of methods that can be 
directly applied in complex samples. For example, electrochemical aptamer-based 
sensors can be directly utilized in undiluted blood because of the extreme 
selectivity of electrochemical detection. The method will allow for development of 
E-AB sensors for new aptamers in a simple, fast and low-cost manner. 
6.2 Future 
 
Aptamer-based cocaine detection with our fluorescence method suffered from 
auto-fluorescence in urine and serum. When the matrix by itself was excited at 358 
nm, endogenous molecules in the matrix gave high fluorescence at the monitored 
emission wavelength of 405 nm. Thus, detection in complex matrices was limited 
to diluted samples which resulted in limited sensitivity. Additionally, the cocaine 
aptamer that was engineered displayed strong cross-reactivity with several small 
molecules that could be present in biological fluids. To solve both issues, Yu et al. 
develop a split-aptamer assay incorporating a fluorophore that is out of the range 
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of most of the endogenous fluorescent molecules.234 Thus, this improved method 
can detect cocaine in 10% saliva below the recommended cut-off limit established 
by the European Union's Driving under the Influence of Drugs, Alcohol and 
Medicines program. A similar approach could be taken to identify a fluorophore 
outside of the interference range that can bind in the aptamer pocket and be 
displaced by the drug target. For example, Sato et al. reported an ATMND-thiazole 
orange conjugate that exhibited the same affinity for abasic sites as demonstrated 
by ATMND alone but with significantly higher excitation (506 nm) and emission 
(530 nm) wavelengths, which are well outside of the auto-fluorescence window of 
biological fluids.235 Indeed, it was demonstrated that the conjugate exhibited 
nanomolar affinity for cytosine and thymine opposite the abasic site but did not 
bind strongly with purine nucleotides. Thus, it is likely that the conjugate could 
retain the same affinity for the cocaine aptamer pocket and be utilized as a signal 
reporting dye. 
We demonstrate the first specific sensor for detection of adenosine in undiluted 
serum over similar molecules such as ATP, ADP and AMP. I would like to apply 
this sensor technology to measure real patient samples. The test would include a 
control healthy population and a diseased population. Generally, adenosine 
concentration is much higher in diseased states (>3 µM) vs. healthy individuals (<1 
µM).73,75,77 The sensor could be used to calculate the concentration of both 
populations and determine a cut-off concentration for disease diagnosis. The 
sensor could also be used to profile the activity of adenosine regulating enzymes 
to discover new small molecule inhibitors of these enzymes which are often  over 
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or under-expressed in diseased states. An important limitation of current 
measurement techniques for adenosine is the inability to measure adenosine close 
to the cell surface, where it is often produced and accumulated. Aptamers have 
been previously immobilized onto cell membranes by conjugation with an 
intercalating group. For example, Tokunaga et al. previously conjugated the ATP- 
cross reactive aptamer with tocopherol as a direct method to anchor the aptamer 
onto cell membranes and monitor ATP release by a fluorescence reporter directly 
modified in the aptamer structure.184 A similar approach could be utilized to 
measure adenosine in situ, providing much more accurate representation of real 
adenosine concentration and production dynamics. To increase the sensitivity, we 
can also modify the aptamer to only bind a single adenosine molecule per aptamer 
instead of the current two. Zhang et al. recently determined that the classic ATP 
aptamer could be engineered to bind only one molecule per aptamer while keeping 
the same stem-loop structure, a similar approach could be taken with our new 
adenosine-specific aptamer.197 This would immediately increase the sensitivity by 
at least two-fold. 
Aptamer truncation was also demonstrated with T5 exonuclease as a key tool to 
develop structure-switching aptamers which have been widely used in 
electrochemical-based sensors. However, the structure-switching functionality of 
the aptamers was not directly measured. Thus, experiments such as circular 
dichroism could be performed to measure the changes in the truncated aptamer 
structure before and after target binding and further comparing the results to fully 
folded aptamers. Urea denaturation studies could also be attempted to observe 
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whether the truncated sequences are fully denatured in the absence of target. 
Additionally, isothermal titration calorimetry must be employed to determine the 
binding affinity and thermodynamics of binding of the truncated sequences as 
compared to the original parent aptamer. Finally, the identified structure-switching 
aptamers must be functionalized with an electroactive group and utilized in E-AB 
sensors to determine their analytical characteristics and functionality in complex 
samples. 
The T5 exonuclease method can also be used independent of aptamer-sensors to 
yield truncated aptamer sequences that can provide higher specificity than fully 
folded aptamers. We previously demonstrated that the truncated aptamer for 
cocaine does not bind ATMND favorably. Several non-specific binders do not 
actively induce structure-switching; thus, specificity is improved upon truncation. 
The method could also potentially be used for development of a SELEX process 
as the enzyme can differentiate between target-binding and non-binding 
sequences, as T5 will fully digest the non-binding sequences while leaving target- 
binding aptamers behind. 
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